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INTRODUCTION 
 
Human African Trypanosomiasis (HAT), or sleeping sickness, is caused by infection 
with parasitic protozoa of the Trypanosoma brucei (T. brucei) subspecies, which are 
introduced to the human bloodstream by the bite of infected tsetse flies in the inter-
tropical regions of Africa.  Trypanosoma brucei gambiense, found in West and 
Central Africa, leads to a chronic form of the disease.  T. b. rhodesiense, found in 
East Africa, leads to a more virulent and acute condition. Once parasites establish 
within the cerebrospinal fluid death is an inevitable consequence of infection unless 
the disease is treated. Sleeping sickness is a re-emerging infectious disease with the 
number of infected individuals presently estimated at more than 300.000 [1], and 
about 55 million people are at risk of infection. No vaccines exist against sleeping 
sickness, and the prospects of prophylactic immunisation are poor since the parasites 
change their surface coat periodically in a process known as antigenic variation [2]. 
Drugs remain the principal means of intervention. Four drugs are currently registered 
[3]. The drug of choice depends on whether the disease is diagnosed before parasites 
have established within the cerebrospinal fluid. Problems associated with the current 
therapies of sleeping sickness include toxicity, resistance and lack of a guaranteed 
supply [4]. 
  
Drug target 
  
New drugs are urgently needed for human African trypanosomiasis. Moreover, as the 
emergence of resistance is likely to be an ongoing problem, a system should be 
established to ensure new products become available on a relative frequent basis. In 
order to act, drugs must specifically inhibit a target within the parasite. 
Trypanosomes diverged early in the eukaryotic lineage [5], and their biochemical 
constitution differs in many respects from that of mammalian cells. Pathways present 
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in trypanosomes, but absent from mammalian hosts, may provide selective targets. 
Systematic sequencing of pathogen genomes is now possible. A natural progression 
from comparative biochemistry has been to proceed to trypanosomatid genome 
sequencing projects to identify new drug target. Trypanothione and its metabolism, 
glucose metabolism and its unusual compartmentalisation within peroxisome-like 
organelles called glycosomes, purine metabolism, lipid biochemistry and polyamine 
metabolism have all been proposed as good targets [6]. 
The gene knockout approach [7] is now widely used to provide evidence on whether 
a gene is essential, and thus a credible target for inhibitory drugs. The discovery that 
RNA interference, a phenomenon whereby double stranded RNA molecules lead to 
suppression of expression of the genes from which they are derived, [8] has led to the 
development of simple techniques enabling inducible suppression of gene expression 
in these parasites. This has offered an accelerated route to loss of gene function and is 
now enhancing the rate at which gene products can be validated as drug targets. 
Proteins like trypanothione reductase, that are unique to trypanosomes, have been 
proposed as ideal targets [9]. However other enzymes, which are present in both host 
and parasite, can also be effective drug target. Indeed ornithine decarboxylase, 
present in both host and parasite, is the only known target for any registered drug 
used against trypanosomatids, being inhibited by eflornithine (DFMO). 
Other enzymes found in both mammalian cells and trypanosomatids can also be good 
drug targets because they have structural peculiarities that can be targeted by 
selective inhibitors. This has been clearly demonstrated in the case of the key 
glycolytic enzyme glyceraldehydes-3-phosphate dehydrogenase (GAPDH). 
Differences in the coenzyme (NAD+) binding site were identified using comparative 
X-ray crystallographic analysis [10]. Structures based on adenosine, as analogues of 
co-factor, were shown to selectively inhibit the trypanosomatid enzymes and also to 
kill both T. brucei and T. cruzi. 
The pentose phosphate pathway (PPP) (Fig.1) is another key pathway of glucose 
metabolism present in most species [11]. . The pathway is developmentally regulated 
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in T. brucei, with all enzymes of the PPP present in the procyclic form and the 
oxidative branch enzymes in the bloodstream form [12]. We have been engaged in 
studies on 6-phosphogluconate dehydrogenase, the third enzyme of this pathway. The 
trypanosomal version differs significantly in sequence when compared to its 
mammalian counterpart and is a validated target for therapy [46]. 
The dehydrogenases of the pentose phosphate pathway (PPP), glucose-6-phosphate 
dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGDH), are 
NADP+ dependent in most organisms. The pathway has two main parts: an oxidative 
branch and a non-oxidative, rearrangement branch. The major functions of the 
pathway are the generation of the reduced coenzyme NADPH and the production of 
ribose 5-phosphate for nucleotide and nucleic acid synthesis. NADPH is essential in 
protecting the organism against oxidative stress and is required for a variety of 
reductive biosynthetic reactions, particularly lipid production. The whole of the PPP 
operates in mammals. The first enzyme of the pathway, G6PDH has been shown to 
be essential for defence against oxidative stress in humans [68]. Serious G6PDH 
deficiency is well known and results in haemolytic anaemia. 
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                                                  Fig.1. Pentose Phosphate Pathway 
 
Action mechanism of 6-phosphogluconate 
dehydrogenase  
 
6PGDH is the third enzyme of the Pentose Phosphate Pathway (Fig. 1), which 
provides both NADPH, required for many biosynthetic and detoxification reactions, 
and also active in protection against oxidative stress, and ribose, essential for 
nucleotide biosynthesis.  
It catalyses the NADP+-dependent oxidative decarboxylation of 6-phospho-D-
gluconate (6PG) to D-ribulose 5-phosphate (Ru5P), via 3-keto 6PG and a probable 1, 
2-enediol as intermediates (Fig. 2) [13,14].  
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Two residues, one acting as an acid and the other as a base are postulated to assist all 
the three catalytic steps of the reaction: dehydrogenation, decarboxylation and keto-
enol tautomerization. These residues, which in the T. brucei enzyme are Glu-192 and 
Lys-185, have been identified on the basis of crystallographic evidence and site-
directed mutagenesis [15-17]. The lysine residue is thought to be protonated in the 
free enzyme and unprotonated in the enzyme-substrate complex, where it has to 
receive a proton from the 3-OH of 6PG as a hydride is transferred from C-3 of 6PG to 
NADP (Fig.2). The resulting 3-keto-6PG intermediate is then decarboxylated to form 
the enediol of 5-phospho-ribulose. At this stage an acid, which is thought to be the 
same Lys-185, is required to donate a proton to the C-3 carbonyl group of the keto-
intermediate to facilitate decarboxylation. Both a base and an acid are needed in the 
tautomerisation of the enediol intermediate to yield the ketone ribulose 5-phosphate 
product, with the acid (Glu-192) required to donate a proton to the C-1 of the enediol 
intermediate and the base (the same Lys-185) accepting a proton from its 2-hydroxyl 
(Fig.2, Fig.3). At the end of the reaction the protonation state of the two catalytic 
groups is the opposite to that at the beginning of the reaction; thus an intramolecular 
proton transfer is required for another cycle of enzyme activity. 
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        Fig. 2.  6PGDH-catalysed reaction and the two main amino acid residues involved. 
 
 
                   
 
  Fig.3. T. brucei 6PGDH active site with the position of the two residues, discussed in the       
             introduction. 
K185 
E192 
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Structure of 6PGDH 
 
The 6PGDH is a homodimer with subunit size 50kDa. The 6PGDH of T. brucei 
shows only a 33% amino acid identity with the mammalian 6PGDH [18]. Identity is 
higher (37.3%) with both the chloroplast and the cytosolic 6PGDH from spinach 
[19]. This may reflect the evolutionary history of the Kinetoplastida, the phylogenetic 
order to which trypanosomes belong, which have been proposed to have derived from 
an ancestor common with the primitive plants Euglenoid algae [20]. A number of 
genes in trypanosomes appear to relate more closely to those of cyanobacteria and 
plastids as well as algal and other plant genes than to those of other eukaryotic 
lineages [20].  The sequence of 6PGDH from 9 different species, Saccharomyces 
cerevisiae, Drosophila melanogaster, Homo sapiens,  sheep, Escherichia coli, 
Lactococcus lactis, Plasmodium vivax, Trypanosoma brucei e Leishmania major, 
have been aligned using the programs MultAlin [21] e ESPript [22] to show the 
conserved amino-acids among species. Of the 482 amino-acids that belong to one 
subunit, 88 are conserved in all species (Fig. 4)[23]. 
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                  Fig. 4. Multiple alignment of 6PGDH from several species. 
 
The 3-dimensional structure of the T. brucei  6-phosphogluconate dehydrogenase has 
been solved at 2.8 Å resolution (Fig. 5)[24]. The sheep liver enzyme, which has 97% 
sequence identity to the human enzyme, has been described at 2 Å [25] resolution and 
enzyme-coenzyme and enzyme-substrate complexes have been reported at 2.3 Å -2.5 
Å resolution [26]. 
The structure of Lactococcus lactis 6PGDH in ternary complex with NADP and the 
product Ru5P or the inhibitor 4-phospho-D-erythronohydroxamic acid (PEX) were 
also reported [27]. 
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The T. brucei monomer 
 
The 6PGDH monomer has three domains (Fig.5). 
The N- terminal “coenzyme” domain (residues 1-178) contains a typical dinucleotide 
binding Rossmann fold (1-130, βA ….βF with intervening helices) and a further 
α−β−α  unit (132-161, αf-βG-αg) with the strand βG antiparallel to the first 6 strands. 
The coenzyme binding site is at the carboxyl ends of the strands of the parallel sheet, 
with the two ribose moieties and the bis-phosphate straddling the sheet. The 
dinucleotide binding fingerprint, at the tight turn following βA, is GxGxxG in the T. 
brucei enzyme while in the ovine enzyme it is GxAxxG as in almost all known 
6PGDHs. As the two subunits of the T. brucei dimer were not crystallographically 
equivalent, slightly different conformations of two loops in the coenzyme domain 
could be seen [15]. Crystallographic symmetry precludes such observations in the 
sheep liver enzyme [24]. The second all “helix” domain (179-441, αh…αr) forms 
one part of the dimer interface and the “tail” (442-478, αs…C terminus) penetrates 
the second subunit (Fig. 6).  
The substrate site lies at the interface between the helical domain and the coenzyme 
binding domain of one subunit and the tail of the second; residues which bind 6PG 
come from all three domains. 
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                                          Fig 5. Monomer of the T. brucei 6PGDH. 
 
 
 
Fig. 6. Dimer of the T. brucei 6PGDH. The two subunits are drawn in blue and in green. 
 
“Coenzyme
” 
“Helix” 
“Tail” 
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The dimer interface  
 
The mode of dimerisation, with the tail of one subunit penetrating the other, is 
conserved between species. Although the dimer interface is structurally well 
conserved, with 106 of the 134 residues contributing to the interface of the parasite 
enzyme structurally equivalent to those in the sheep enzyme, only nine fully 
conserved residues have a major role in dimer formation. Three of these residues are 
part of the tail domain. The most significant difference in the nature of the interface is 
where the tail of one monomer threads through the other and contributes to the 
substrate binding site. The tail of the T. brucei enzyme is highly charged: 13 residues 
of 37 are aspartate, glutamate, histidine, lysine or arginine; the sheep enzyme has 
only seven charged residues in the longer (48 residues) tail. The significance of this is 
not yet certain but the profound distinctions at the interface may be amenable to drug 
targeting as techniques for disturbing protein interactions are developed. 
 
Substrate binding site 
 
Of the 19 residues within 4 Å of 6PG (Fig. 7): Asn 104 -102s (the sheep numbering is 
denoted by a lower case s), Ile 129 - Val 127s, Ser 130 - 128s, Gly 131 - 129s, Gly 
132- 130s, Lys185 - 183s, His 188-186s, Asn 189 - 187s, Glu 192 - 190s, Tyr 193-
191s, Ser 261- Gln 259s, Lys 262 -260s, Gly 263-261s, Thr 264- 262s, Arg 289- 
287s, Ile 373- 366s, Arg 453-446s, Phe 456- 449s, His 459- 452s, as bound in the 
sheep enzyme or modelled into the T. brucei enzyme, 14 are conserved for all species 
studied to date. Five of the substrate neighbours come from the coenzyme domain, 
eleven from the helical domain and three from the tail of the second subunit. The 
conserved lysine (Lys 183s, Lys 185) predicted to be the base in the reaction is on 
αh; the five residues in this helix, which interact with substrate, have moved less than 
0.5 Å in the T. brucei  6PGDH compared to the sheep structure. 
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There are, however, several residues that are second nearest neighbours to the 
substrate and differ in the T. brucei enzyme from sheep. They include Thr 102 (Gly 
100s), Ala 141 (Ser 139s), Phe 143 (Met 141s), Ser 190 (Gly 188s), Leu 196 (Met 
194s), Leu 374 (Ile 367s), Ser 450 (Gln 443s and Ser only in T. brucei) and Arg 458 
(Ala 451s and Arg only in T. brucei). The Nη 1 of Arg 446s (Arg 453) is a ligand to 
the 6-phosphate of 6-phosphogluconate. In the sheep enzyme Arg 446s is oriented by 
a hydrogen bond from its Nε to the Oε1 of Gln 443s (equivalent to Ser 450 in T. 
brucei), while Gln 443s Nε2 interacts with the carbonyl of Gly 258s (equivalent to 
Gly 260 in T. brucei). Residue 443s is therefore important in constraining the 
movement of Arg446s and defining the orientation of the phosphate of 6PG. In T. 
brucei 6PGDH, the hydroxyl of Ser 450 hydrogen bonds to the main-chain carboxyl 
oxygen of Arg 258, but there is no interaction with Arg 453. 
Arg 458 interacts with the highly conserved Glu 133 (Glu 131s), which should have 
further implications for interaction with substrate since the carboxyl oxygens of 6PG 
interact with residues of the βF-αf turn (130- 132, 128s- 130s). These residues have 
moved almost 1 Å from their position in the sheep enzyme; the movement is 
correlated with the differing inter-domain hinge angles. Despite the conservation of 
first neighbours to 6PG, these changes provide means by which the affinity for 
substrate and substrate analogues may vary between species, and suggest possible 
targets for substrate analogue and potential drug interaction. 
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                                                Fig. 7.  Substrate binding site. 
 
Coenzyme binding site 
 
The equivalent folds of the  T. brucei and sheep enzymes suggest that coenzyme 
binding will be similar although differences do exist, and the recent targeting of 
selective inhibitors to the NAD+ binding domain of trypanosomatid GAPDH 
demonstrates how subtle differences in coenzyme binding may be exploited in 
selective drug design [10]. The coenzyme binding domain of 6PGDH has 70 residues 
identical in the sheep and T. brucei enzymes (Fig. 8). The oxidised coenzyme 
analogue 8-bromoadenine dinucleotide phosphate Nbr8ADP+, can be diffused into 
crystals of sheep 6PGDH apo-enzyme. It binds in a manner similar to that seen in 
many enzymes with the dinucleotide binding fold, with the adenine ribose 
approaching the βA-αa tight turn, the “coenzyme fingerprint”. On binding the 
analogue, there is little main-chain movement: 0.25 Å for all main-chain atoms 
within 10 Å of the analogue [26]. Of the 17 residues of sheep 6PGDH, which are 
within 4 Å of the active oxidised coenzyme analogue, 12 are identical for the T. 
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brucei and sheep structures. The Km for NADP+ for T. brucei 6PGDH is 1 µM while 
that for sheep enzyme is several times higher ranging from 5.7-8.9 µM depending on 
pH and ionic strength [28]. Sequence differences at the coenzyme binding site may 
affect the affinity for NADP+ between species. 
The mean main-chain movement for the 17 residues of the sheep enzyme on binding 
the analogue is 0.31 Å; only Lys 75s moves significantly (0.77 Å). Hydrogen bond 
interaction of the sheep enzyme with oxidised coenzyme is predominantly that of the 
2’-phosphate and adenine ribose to triplet Asn 32s, Arg 33s, Thr 34s directly 
following βB (Asn 31, Arg 32, Thr 33 in  T. brucei). 
The additional hydrogen bonds are to the nicotinamide amide function from a 
conserved methionine of the fingerprint (Met 13s) and from a glutamate of αf (Glu 
131s) conserved in 68 of 70 species. All residues with side-chain hydrogen bonds are 
conserved between sheep and T. brucei, though it should be noted that, in two other 
species, a tyrosine replaces the arginine 32, (33s), which interacts with the 2’-
phosphate. The most important changes in sequence between the sheep and T. brucei 
enzymes, which may affect binding are Ala 11s to Gly 10, Lys75s to Gln 77 and Phe 
83s to Thr 85. 
The Cβ of Ala 11s in sheep 6PGDH protrudes into the bis-phosphate binding site. 
This residue corresponds to the central glycine of the generic fingerprint; the very 
small number of direct interactions of the bis-phosphate to the protein is almost 
certainly a consequence of this alanine. The substitution of glycine for alanine in the   
T. brucei enzyme should allow direct interactions between the enzyme and the 
NADP+ bis-phosphate and has a further consequence in that the highly conserved 
valine 11 (Val 12s) faces towards the putative nicotinamide site in T. brucei 6PGDH 
and away from it in the sheep enzyme. Val 11 would provide further Van der Waals 
contacts for the nicotinamide ring. The substitution of Gly 10 in the T. brucei enzyme 
would suggest a tighter binding of coenzyme as reflected in the higher affinity.   
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                                             Fig. 8. Coenzyme binding site. 
 
Functional asymmetry  
 
6PGDH is a homodimer, but, in many species, it shows functional asymmetry [29-
35]. For instance, both the yeast and sheep liver enzyme bind covalently two 
molecules of periodate-oxidized NADP, but, in the presence of 6PG, a half-site 
reactivity is acquired with only one subunit binding the NADP analogue, with the 
other subunit unable to bind even the adenylic moiety of the coenzyme [29,30]. These 
experiments suggest that when one subunit is involved in the ternary complex 
enzyme-6PG-NADP, the other subunit is unable to bind NADP and is thus inactive 
(Fig. 9). Also 6PGDH from human erythrocytes shows a half-of-the-sites reactivity, 
indeed it is able to bind two molecules of NADP, but only one of NADPH, 
suggesting that the binding of NADPH  to one subunit affects the conformation of the 
other NADPH binding site; the free enzyme is unable to bind NADP and NADPH at 
the same time [32].  
Moreover, negative cooperativity for NADP has been found in human erythrocyte 
[32] and rat liver [33] 6PGDHs, and stopped-flow experiments with the sheep 
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enzyme have indicated in the first turnover the formation of only one NADPH 
molecule per enzyme dimer [31]. The substrate binding site is made up of residues 
from both subunits, allowing the communication between the two active sites, which 
has also been shown by the decarboxylation activation of 6-phospho-3-keto-2-
deoxygluconate by 6PG [34].  
                                                 Fig. 9. Half of the site mechanism 
 
Half-of-the-sites reactivity and conformational 
changes 
 
All data presented so far point to half-of-the-sites reactivity and to conformational 
changes induced by 6PG. The half-of-the-sites reactivity requires that a change of one 
parameter of one subunit is communicated to the other subunit. The crystallographic 
studies have indicated that each active site of the enzyme contains amino acid 
residues from the coenzyme and the helix domains of one subunit and the carboxy 
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terminal tail of the other. Thus 6PG, binding to one active site, comes in contact with 
residues of all three domains of the two subunits; this binding may cause a shift of 
one subunit with respect to the other, possibly causing a conformational change not 
only in this active site but also in the other and in the dimeric interface [37]. However 
crystallographic data do not show any significant conformational change upon 
binding of substrate or coenzyme. 
Instead, in solution, the binding of 6PG, phosphate or sulphate causes conformational 
changes in the enzyme molecule. Indeed, in their presence, the activity of yeast 
6PGDH is much more stable against inactivation by seven proteolytic enzymes, acid, 
heat, cystamine, DTNB, urea, SDS [38], and different inactivating chemical reagents 
[39,40-44]. In presence of phosphate buffer the order of binding of 6PG and NADP 
to the enzyme is different than in triethanolamine buffer [31] and the reactivity of 
several thiol groups with DTNB reduced [45]. 6PG increases the reactivity with 
periodate-oxidized NADP [45,29]. All these data indicate that the binding of these 
compounds modifies in part the conformation of the enzyme in solution, making it, 
perhaps, more rigid. 
All the crystallographic data were obtained with crystals prepared in ammonium 
sulphate. In the crystals each enzyme subunit has firmly bound three sulphate 
ions[15]; each of these ions bridges different segments of the protein chain in the 
same or in a different subunit stabilizing the conformation of the enzyme. Two of 
these sulphates bind to the active site and one is displaced by 6PG. The finding that 
the enzyme in the crystals does not show conformational change in presence of 6PG 
could be due to the fact that these changes were already induced by bound sulphate 
ions. 
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A hypothesis of alternating-site mechanism 
 
It has been advanced [34] the hypothesis that the two enzyme subunits have an 
alternating role in the oxidative decarboxylation: while one of the two equal subunits 
catalyses the redox reaction, the other subunit, with a different conformation, 
catalyses the decarboxylation and tautomerization reactions. Then the two subunits 
alternate their conformation and role. On the basis of now available data, the 
molecule of the dimeric anzyme has the following properties: 
1. presents a half-of-the-sites reactivity, 
2. in one turnover produces only one NADPH molecule, 
3. is able to bind simultaneously, but in different subunits, the substrate and its 
oxidation product, 
4. when one subunit binds 6PG, the other is able to decarboxylate the 
intermediate, 
5. when one active site binds 6PG and NADP, the other is unable to bind the 
coenzyme, 
6. NADPH activates the reactions of decarboxylation and tautomerization, but the 
activation does not depend on its redox role. 
In Fig. 10 a detailed hypothesis on the mechanism of action of 6PGDH is presented. 
For the sake of simplicity “INT” is the intermediate of the oxidative decarboxylation 
and “Ru5P” indicates both the ketonic and enolic forms of Ru5P. Likely, in this 
Figure ”decarboxylation” collectively indicates the tautomerization reaction and the 
release of carbon dioxide.  
According this hypothesis, 6PG binds to one (B) of the two structurally equal 
subunits, inducing in both a different conformational change (step 1). Also NADP 
binds to the same subunit. Subunit B catalyzes (step 2) the redox reaction producing 
the intermediate and NADPH. Now 6PG binds to subunit A (step 3) inducing in both 
subunits a conformational change which promotes subunit B to catalyze the 
decarboxylation of the intermediate. The binding of NADP to subunit A induces the 
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release of the oxidative decarboxylation products from subunit B (step 4). Now in 
subunit A the redox reaction occurs (step 5) with the production of NADPH and the 
intermediate. Step 6 and 7 are a repetition of step 3 and 4, but the subunits exchange 
their role. 
 
 
Fig. 10 Hypothesis of half-site mechanism 
 
Inhibitors of T. brucei 6PGDH  
 
Two reviews have dealt with T. brucei 6PGDH inhibitors as lead compounds for new 
drugs against African trypanosomes [46,47]. Since then, new better inhibitors have 
been found, which mimic the transition-state and high-energy intermediates of the 
enzymatic reaction of 6PGDH [48]. Hydrophobic analogues of these also revealed 
some anti-parasite activity [54]. A number of phosphorylated carboxylic acids 
derived from aldose sugars were tested against 6PGDH, two particularly notable 
inhibitors were identified. Both 4-phospho-D-erythronate (4PE) and 5-phospho-D-
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ribonate (5PR) (Fig. 11, compounds 1 and 2) were competitive with respect to 
substrate, with Ki values for the T. brucei 6PGDH equal to 130 and 950 nM 
respectively. Their selectivities for the T. brucei 6PGDH over the sheep liver one 
(ratio Ki sheep/ Ki T. brucei) were measured at 83-fold and 70-fold respectively. Ki 
values for both are under the Km for 6PG (= 3.5 µM), indicating that they mimic high-
energy reaction intermediates (Fig. 2) rather than the substrate per se [46,49]. 
 
 
Fig. 11. Structures of some substrate analogues (Ac=Acetyl group). 
 
 
Another potent and selective T. brucei 6PGDH inhibitor is 4-phospho-D-
erythronohydroxamate (Fig. 11, compound 3), synthesized specifically to mimic the 
high-energy intermediates produced following the second (decarboxylation) step of 
the catalyzed reaction, shown in Figure 2. This hydroxamate, with a Ki = 10 nM and 
selectivity of 254-fold for the parasite enzyme over the sheep liver enzyme, is the 
compound with the highest affinity for the T. brucei 6PGDH reported to date and it 
also shows the highest selectivity for the parasite over the sheep liver enzyme [48]. 
 In Table 1, inhibition constants versus 6PG (Ki) at pH 7.5 (which is the enzyme 
optimum pH) for all T. brucei 6PGDH inhibitors, which are shown in the figures 
included in this text, are reported, together with selectivity values over the sheep liver 
enzyme (ratio sheep liver 6PGDH Ki / T. brucei 6PGDH Ki).  
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Compound 
 
Ki versus substrate 
(µM) 
Selectivity 
(Ki sheep/ Ki 
T.brucei) 
1 0.13 83 
2 0.95 70 
3 0.01 254 
4 1.52 25.7 
5 0.08 4.5 
6 0.035 31.4 
 
                           Table 1. 6PGDH inhibition constants of compounds in fig. 11. 
 
To better understand why these analogues have high affinity and to help in rational 
drug design, we undertook a thermodynamic characterization of substrate and 
analogue binding to T. brucei 6PGDH, in both binary and ternary complexes, with 
NADP, the coenzyme analogue 3-amino-pyridine adenine dinucleotide phosphate 
(aPyADP) (Fig.18) or NADPH. We show that the ternary complexes with the 
oxidized coenzyme and with aPyADP display half-site reactivity, and that 4PE, but 
not 5PR, is a transition state analogue (Fig. 12). 
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Fig.12. Protonation states of the two main active site amino acid residues in different reaction steps   
and in the complexes with 4PE or 4PEX. 
 
The reverse reaction 
 
Despite the catalytic mechanism of 6PGDH has been widely investigated, very little 
is known on the last steps of the reaction, and in particular on the conversion of the 
dienol to Ru5P. In the oxidative decarboxylation this step follows the irreversible 
release of CO2, so its weight on the overall kinetics is shielded. The enzyme follows a 
rapid equilibrium bi-ter sequential mechanism, with random order of substrate 
addition both in the direct reaction, the oxidative decarboxylation, and in the reverse 
reaction, the reductive carboxylation [75]. The enzyme dependent stereospecific keto-
enol conversion of Ru5P occurs even in the absence of CO2 [14], and  it has been 
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shown that this reaction has the absolute requirement of NADPH, that does not have 
a redox role and can be substituted by non-reducing analogues [73]. The only 
information about the carboxylation reaction is  that CO2 is the true substrate, but the 
presence of a CO2 binding site has not been clearly demonstrated.  
2H and 13C isotope effects have shown the both dehydrogenation and decarboxylation 
steps are partially rate limiting, while solvent isotope effect evidenced a kinetically 
significant isomerization step preceding the dehydrogenation.  A study of the kinetic 
isotope effects in the reverse reaction, the reductive carboxylation, could give the 
additional information required for a better comprehension of the “hided” steps, and a 
complete description of the energy profile of the reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
AIM OF THE THESIS  
 
 
6-Phosphogluconate dehydrogenase is a validated drug target in African 
trypanosomes [46].  A number of compounds have been discovered which show 
selective and potent inhibition of the parasite enzyme [53]. The structure of the 
enzyme from both the trypanosome and mammalian source is known; there do not 
appear to be significant structural differences between the enzymes, although it has 
been possible to discover very selective inhibitors of the trypanosome enzyme [24]. 
Unfortunately the inhibitors discovered do not have activity against trypanosomes, 
which is probably due to their highly charged and polar nature [53]. Nevertheless 
some recently developed parent compounds with phosphate masking groups, which 
are able to deliver active compounds into parasites, show a good level of 
trypanotoxicity [54]. One objective of this work is to better understand the inhibition 
mechanism of some substrate analogues in the 6PGDH of T. brucei through 
thermodynamic characterization. 
Another objective is to investigate the action mechanism of 6PGDH and this has been 
done by two different approaches. Firstly we have prepared the mutants of Glu192 
and Lys 185, the residues that are postulated to assist the catalytic steps, and we have 
investigated the thermodynamics of substrate binding to the enzyme through 
isothermal titration calorimetry (ITC). The comparison of ITC data of the wild type 
with the mutant enzymes is helping us to understand the role of these residues in the 
change induced in the enzyme by the substrate binding. Moreover since the lysine 
residue is thought to be protonated in the free enzyme and non protonated in the 
enzyme-substrate complex, this raises the question whether the binding of the 
substrate causes a proton release in the medium or an intramolecular proton transfer 
occurs. To better understand the protonation state of the enzyme-substrate complex, 
we have studied by ITC the release-uptake of hydrogen ions during the formation of 
the enzyme-6PG complex in the 6PGDH from T. brucei by comparing the wt enzyme 
with several mutants of the enzyme. 
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A second approach was the study of the reverse reaction of the 6PGDH by kinetic 
isotope effects. This approach, together with the data already present in literature, 
allows the construction of the energy profile of the whole reaction. 
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MATERIALS AND METHODS 
 
 
Preparation of wild type 6-Phosphogluconate 
Dehydrogenase of  T. brucei. 
 
Overexpression of the T. brucei enzyme in E. coli. 
 
 Plasmid pT7gnd was transformed into E.coli strain BL21 (DE3). pT7gnd is derived 
from cloning of the gene gnd into the vector pET3a, with the ATG initiation codon 
oriented adjacent to the bacteriophage T7 RNA polymerase promoter. BL21 (DE3) 
are E. coli cells with the phage DE3 encoding T7 RNA polymerase under the control 
of the lacUV5 promoter. A single transformed colony was grown overnight at 37°C 
in LB/amp (Luria Bertani broth plus ampicillin). The next morning the overnight 
culture (30 ml) was added to 0.8 liters of LB/amp and grown with agitation in a 2-
liter conical flask at 28°C until the culture reached an optical density of 0.6 at 600nm. 
At this point the lac operon inducer isopropylthiogalactopyranoside (IPTG) was 
added to a final concentration of 0.4 mM. The culture was left incubating at 28 °C for 
4 h, after which the cells were harvested by centrifugation at 4000 rpm for 10 
minutes. 
 
Purification of plasmid DNA  
 
Plasmid DNA  purification was performed by using a Miniprep Kit (Quiagen). This 
method consists of three basic steps: alkaline lysis of bacterial cells, selective 
absorption of plasmid DNA on a silica membrane and washing and elution of plasmid 
in low ionic strength buffer. It is an easy and fast method that allows to get pure DNA 
for cloning and for sequencing. 
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Determination of DNA concentration  
 
The Determination of DNA concentration is done both by ultraviolet spectrometry 
(UV) and valuation after agarose gel electrophoresis. 
 
Spectrophotometric determination 
 
The DNA concentration was assayed both at 260 nm and 280nm: 
 
DNA Concentration (µg/ml) = A280nm x   50 µg/ml 
 
The ratio OD260/OD280 must be ≥ 1.7 for pure preparation of DNA, if the ratio is < 1.7 
it means that in the sample there is protein contamination. 
 
Electrophoresis in agarose gel  
 
The agarose gel was prepared in buffer TAE (0,04 M Tris, 1mM EDTA 5 mM 
sodium acetate, taken to pH 7.5 with glacial CH3COOH) adding ethidium bromide 
0,4 µg/ml. Before loading, 0.2 volumes of  the following buffer: 0.25 % (p/v) 
bromine phenol dye, 100 mM EDTA, 50% (v/v) glycerol is added to the sample. 
After the electrophoretic run, DNA is seen by UVtransillumination, for the 
fluorescence effect of the  ethidium bromide that binds to double stranded DNA. 
 
 
 
+ 
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Site- Directed Mutagenesis 
 
The QuickChange II site-directed mutanegesis Kit (Stratagene) was used to introduce 
nucleotide changes according to manufacturers’ specifications directly into the T. 
brucei 6PGDH gene, cloned into the expression vector pET3a.  
The plasmids extraction was from bacterial stock JM109 (Genotype: F’ [traD36, 
proAB+, laclq, lacZ∆(M15)], recA1 ednA1 gyrA96 thi hsdR17 supE44 relA1 ∆(lac-
proAB). The stock JM109 has been used for cloning of the gene of  the wild type 
enzyme. The QuikChange II site-directed mutagenesis method is performed using 
PfuUltra™ high-fidelity (HF) DNA polymerase for mutagenic primer-directed 
replication of both plasmid strands with the highest fidelity. The basic procedure 
utilizes a supercoiled double-stranded DNA (dsDNA) vector with an insert of interest 
and two synthetic oligonucleotide primers, both containing the desired mutation (see 
Figure 13). The oligonucleotide primers, each complementary to opposite strands of 
the vector, are extended during temperature cycling by PfuUltra HF DNA 
polymerase, without primer displacement. Extension of the oligonucleotide primers 
generates a mutated plasmid containing staggered nicks. Following temperature 
cycling, the product is treated with Dpn I. The Dpn I endonuclease (target sequence: 
5´-Gm6ATC-3´) is specific for methylated and hemimethylated DNA and is used to 
digest the parental DNA template and to select for mutation-containing synthesized 
DNA. (DNA isolated from almost all E. coli strains is dam methylated and therefore 
susceptible to Dpn I digestion.) The nicked vector DNA containing the desired 
mutations is then transformed into XL1-Blue supercompetent cells. 
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Fig. 13. Overview of the QuickChange II site-directed mutagenesis method. 
 
In table 2 the sequence of one of the two oligonucleotides for every mutation is 
reported. 
 
K185H 5’-GGATCATGCGTGCATATGTACCACAATTCG-3’ 
K185R 5’-GGATCATGCGTGCGTATGTACCACAATTCG-3’ 
E192Q 5’-GATGTACCACAATTCGGGTCAATACGCCATTTTGCAAATCTG-3’ 
H188L 5’-GGCGTATTCACCCGAATTAAGGTACATCTTCACGCATGATCCC-3’ 
C372S 5’-GCCCTGCAAAATGCTACCGGCGCGGA-3’ 
 
Table 2 Primer  oligonucleotides synthetized by of MWG-biotech AG. 
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The reaction protocol is: 
reaction buffer  (10X) 5µl 
dsDNA template (5 -50 ng) 2 µl 
Forword Oligonucleotide (125 ng) 12.5 µl 
Reverse Oligonucleotide (125 ng) 12.5 µl 
dNTP mix 1 µl 
ddH2O  to a final volume of a 50 µl 
 
Then add 
1 µl di PfuTurbo DNA polymerase (2.5 U/µl) and  let things go the reaction in the 
following way: 
 
Segment Cycles Temperature Time 
1 1 95 C° 30 seconds 
2 12-18 
 
 
95 C° 
55C° 
68C° 
30 seconds 
1 minute 
1 minute/kb  of plasmid length 
 
 
Following temperature cycling, place the reaction on ice for 2 minutes to cool the 
reaction to ≤ 37°C. 
Add 1 µl of  Dpn I restriction enzyme (10U/ µl), and gently  mix reaction by 
pipetting the solution. Spin down the reaction mixtures in a microcentrifuge for 1 
minute and immediately incubate reaction at 37°C for 2 hours to digest the parental 
supercoiled dsDNA.  
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Transformation into XL1- Blue Supercompetent Cells 
 
Gently thaw the XL1- Blue supercompetent cells on ice. For each sample reaction to 
be transformed, aliquot 50 µl of the supercompetent cells in a tube.  
Transfer 1 µl of the Dpn I- treated DNA from each sample. Swirl the transformation 
reactions gently to mix and incubate the reactions on ice for 30 minutes. 
Heat pulse the transformation reactions for 45 seconds at 42°C and then place the 
reactions on ice for 2 minutes. 
Add 0.5 ml of NZY+ broth (10g of NZ amine, 5g of yeast extract,  5g of NaCl 12.5 
ml of 1 MgCl2, 12.5 ml of 1 M MgSO4 and 20ml of 20% (w/v) glucose per liter 
adjust pH 7.5) preheated to 42°C and incubate the transformation reactions at 37°C 
for 1 hour with shaking at 225-250 rpm.  
Plate 250 µl of each transformation reaction on agar plates containing the appropriate 
antibiotic for plasmid vector.  
Incubate the transformation plate at 37 °C for > 16 hours. 
 
Transformation into E. coli strain BL21 (DE3) 
 
The following steps are the extraction of plasmidic DNA from a single colony and 
sequencing of the entire coding region of mutants T. brucei 6PGDH to check that 
only the single mutation is present, using the dideoxynucleotide chain-termination 
method. Once mutated sequence is obtained, it is introduced into E. coli strain DL21 
(DE3) for inducible expression. 
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Enzyme purification 
 
The recombinant T. brucei 6PGDH, overexpressed in Escherichia coli, was purified 
according to a technique that was slightly modified compared to the original of 
Barrett [49,50]. 
Cells were harvested by centrifugation (4,000 rpm, 10min), resuspended in 15ml of 
cell lysis buffer (50 mM TEA, 0.1 mM EDTA and 1mM βmercaptoethanol pH 7.5) 
and sonicated. 
Cell debris and insoluble material were then spun down (40,000rpm, 30min). The 
supernatant was applied to a 15 ml DEAE-Sepharose column equilibrated with TEA 
buffer, which was then washed with the same buffer and the flow through material 
absorbing at 280 nm was loaded directy onto a 5 ml 2’,5’-ADP-Sepharose column, 
equilibrated with TEA buffer diluted 50 x. 
After washing, the enzyme was eluted with Na4P2O7 150 mM containing 1mM 
EDTA pH 7.2 and the specific activity assayed in buffer containing 0,6mM 6PG and 
0.26 mM NADP+. 
The whole purification lasted less than one day and was monitored both by SDS-
PAGE and activity assays. Enzyme was stored in the presence of 50% glycerol at 
 -20°C. 
 
Enzyme activity 
 
One unit of enzyme activity is the amount of enzyme that produce one µmol of 
NADPH in one minute. The absorptivity molar to 340 nm of NADPH is 6,220. The 
specific activity of the enzyme has been calculated as the number of UI divided by 
the number of mg of protein. 
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Determination of protein concentration  
 
Protein content was determined with the spectrophotometer at 280 nm, assuming that 
a solution containing 1mg/ml of protein have an absorbance of 1 O.D. A solution 
containing 1 mg/ml of pure 6PGDH has at 280 nm an absorbance of 1.023. Since a 
single subunit of 6PGDH has a molecular weight of 52 kDa, in 1mg of protein there 
are 19.2 nmol of subunit. 
 
 
Assay of activity for 6PGDH dehydrogenase  
 
The assay is based on kinetic measurement of NADPH that has a maximum 
absorption at 340 nm. The reaction mixture contains 0.6 mM 6PG and 0.26 mM 
NADP in 50mM TEA buffer pH 7.5 with EDTA 0,1mM. The initial velocity is 
measured adding 15 µg of 6PGDH enzyme to 1 ml of reaction mixture, which is 
followed spectrophotometrically, at 340 nm, for the reduction of NADP. 
 
Electrophoresis in polyacrylamide  gel (SDS PAGE) 
 
4 µg/ µl of enzyme are denatured at 100°C for 5 minutes in the presence of the 
reducing agent 2-Mercaptoethanol and loaded onto a gel of polyacrylamide. The 
migration has been made into electrophoresis buffer during 45 minute with an 
amperage of 25 mA. The proteins were coloured with a solution of Comassie blue 
(3% p/v Comassie Brillant Blue, 40% v/v acetic acid, 40% v/v methyl alcohol, in 
water)  at room temperature. 
Destaining is done in 7% v/v acetic acid, 7% v/v isopropyl alcohol, 1% methyl 
alcohol. 
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Preparation of inhibitors 
 
Ribose-5-phosphate and erythrose-4- phosphate were purchased. 5PR and 4PE were 
prepared by bromide oxidation [51] of ribose-5-phosphate and erythose-4-phosphate, 
respectively. The concentration of 5PR and 4PE were determined by measuring the 
concentration of organic phosphate [52]. 
 
Determination of the kinetic parameters and pH 
studies 
 
All assays were performed, in the direction of oxidative decarboxylation of 6 
phosphogluconate, measuring the initial rate, when no deviation from linearity was 
observed (the minimum time for linearity was 1 min with the lowest concentration of 
NADP). Measurements were performed at 20°C either spectrophotometrically 
measuring at 340 nm the production of NADPH in a Kontron Uvikon 930 
spectrophotometer. Concentrations of NADP+ and 6-phosphogluconate were 
determined enzymatically.  
Rates obtained were always strictly proportional to the amount of enzyme added. 
Kinetics parameters were determined from Lineweaver-Burk plots. For determination 
of Km for 6PG, NADP was at a concentration of 0.2mM, while concentrations of 6PG 
were varied between 6 and 50 µM. For determination of Km for NADP, the 6PG were 
at a concentration of 0.5mM, while concentrations of NADP were varied between 5 
and 40 µM.  The buffers for the different pH ranges were used in combination at 
10mM each: TEA/HCl pH 7.5-8.4, Hepes/NaOH pH 6.8-8.2, MES/NaOH pH 5.5-6.7. 
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Reactivity of cysteines 
 
The method (G. Ellman reaction) is based on the capacity of sulphidrilic groups of 
cysteines to react with 5,5- ditiobis-2-nitro benzoic acid (DTNB), developing a 
spectrophotometrically measurable complex.  
The reactivity of cysteines in the reaction has been measured in TEA buffer pH 7.5 at  
20 °C, using a molar ε at 412 nm of 13600 for residue. The enzymes were used at a 
concentration of 4 µM. 
 
Isothermal  titration calorimetry  
 
Isothermal  titration calorimetry  (ITC) is suitable for characterizing both low affinity 
interactions (e.g. protein network regulation and natural ligands) and high affinity 
interactions (e.g. rational drug design). Considering the advanced technological level 
reached as well as the outstanding quality of the information accessible through this 
technique, ITC is expected to play a very prominent role in the next years in the areas 
of rational drug design and protein  network regulation. 
Calorimetry measures directly the heat associated with a given process, which, at 
constant pressure, is equal to the enthalpy change in that process, ∆H. Due to 
sensitivity and accuracy reasons, the calorimeters used to characterize binding 
processes belong to the category of titration calorimeters with dynamic power 
compensation operating at constant temperature (isothermal titration calorimetry). A 
detailed description of the instrument and of the technique can be found in the 
literature [56-64]. Briefly, the macromolecule solution is located inside the sample 
cell and ligand solution in the injector syringe. A feedback control system supplies 
thermal power continuously to maintain the same temperature in both reference and 
sample cells. Any event taking place in the sample cell, usually accompanied by heat, 
will change the temperature in that cell and the feedback control system will 
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modulate the power supplied in order to minimize such temperature imbalance. A 
sequence of injections is programmed and the ligand solution is injected periodically 
into the sample cell (Fig. 14). 
Integration of the calorimetric signal and nonlinear least-squares analysis of the 
resulting binding data were performed to determine the equilibrium association 
constant, Ka, the binding enthalpy, ∆H, and the stoichiometry of the interaction, n. 
The Gibbs free energy of binding, ∆G, and the entropic contribution to the binding 
free energy, ∆S, were calculated from the resolved parameters using the relationships: 
 
          ∆G = - RT ln Ka 
         ∆G =∆ H - T ∆S
 
   
 
                                 Fig. 14. Scheme of microcalorimeter ITC. 
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ITC measurements  
 
Before each experiment, the enzyme was dialysed exhaustively and the titrant was 
diluted in dialysis buffer. All solutions were properly degassed before the titration 
experiments. The enzyme (4-6 µM dimer) was placed in the stirred cell and titrated 
with a total of 23 injections of 10 µL of ligand, at 380 s intervals. An initial 
preinjection of 5 µL volume was made, and the result from this injection was not 
used for data analysis. Heats of dilution and mixing, obtained by blank titrations, 
without the enzyme, were subtracted from the heats obtained with enzyme titrations. 
For ternary complex studies, the first ligand was added at the same concentration in 
both enzyme and titrant to keep the concentration constant during the experiment. 
The enzymatic activity was measured before and after each experiment to verify 
whether enzyme inactivation occurred during titration. 
Experiments were performed in 50 mm buffer, with 0.1 mM EDTA and 1 mM 2-
mercaptoethanol. At pH 7.5 three buffers were used: Hepes (∆Hion = 5.03 kcal mol-1), 
triethanolamine (∆Hion = 7.932 kcal mol-1) and Tris (∆Hion = 11.3 kcal mol-1). At 
different pH other buffers were also used: Cacodylate (∆Hion = 0.7 kcal mol-1) and 
MOPS (∆Hion = 5.22 kcal mol-1). 
The buffer-independent binding enthalpy ∆H0 and the number of hydrogen ions 
exchanged were calculated by the least-squares fitting of the experimental enthalpy in 
different buffers: 
 
                                
obsobs
obsobs
HH
HH
nH 21
21
∆−∆
∆−∆
=
+
 
 
0obs ionH H nH H
+∆ = ∆ + ∆
 41 
where ∆Hobs is  binding enthalpy experimentally observed, while ∆Hion is the buffer 
ionization enthalpy. 
Measurements were performed at 20 °C in a VP-ITC microcalorimeter (Microcal, 
Northampton, MA, USA), and the data were fitted by nonlinear least-squares fitting 
using OriginTM software provided by the instrument manufacturer. 
 
 
Fluorescence measurements 
 
Titration of the 6PGDH-aPyADP complex with 6PG was performed fluorimetrically, 
with a Perkin-Elmer LS55 spectrofluorimeter at 20°C. By this method the decrease of 
fluorescence emission by the aPyADP at 410nm, on addition of 6PG was measured 
(excitation at 330nm). 
1ml of solution containing  19 µM enzyme and 350 µM aPyADP was titrated with 
additions (1-2 µl each) of 5.54 mM 6PG. 
The dissociation constants were estimated by using Scatchard plots in the form: 
        
                                       [ ] ( )FFKsubstrate
F
d
∆−∆=∆ max
1
 
                    
where ∆F is the observed fluorescence decrease, and ∆Fmax the decrease at infinite 
substrate concentration.  
 
Isotope effects  
 
6PGDH from Candida Utilis was purified as already described [71].  The specific 
activity of the purified enzyme was 46 µmoles min-1mg-1.  Stereospecifically labeled 
(1h), (1d) and (1t) 1Ru5P were prepared enzymatically from 6PG [14].  1(1t)Ru5P 
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was prepared as previously described [14], and the specific activity of purified Ru5P 
was 58 cpm/nmole.  For the preparation of 1(1d)Ru5P, buffer was prepared in 99.9% 
D2O, liophylized two times to remove exchangeable hydrogen, and redissolved in 
D2O.  The pH (pD) was calculated from pHmeter reading + 0.3.  The enzymes used 
in the preparation were previously precipitated by 70% saturated ammonium sulfate, 
washed two times with 70% saturated ammonium sulfate in D2O, and finally 
dissolved in the buffer.  The isotopic substitution was estimated by NMR and was 
found 94%.  Ru5P was purified from the reaction mixture by ion exchange 
chromatography and used within two days.  When the Ru5P was stored for longer 
times, it was rechromatographed before the experiments.  The concentration of Ru5P 
was determined colorimetrically [72].  1,6-NADPH was prepared by NaBH4 
reduction of NADP+ and purified by DEAE Sepharose chromatography as already 
reported [73]. 
 
Isotope exchange measurement 
 
Tritium release from 1(1t)Ru5P was measured as previously reported [73].  For the 
measurements of tritium uptake, (1h)Ru5P and (1d)Ru5P were dissolved at the 
desired concentrations in Tris-acetate buffer, containing tritiated water (specific 
radioactivity 9.7 cpm/nanom).  Contaminating CO2 was removed from the buffer by 
purging the solution with helium.  Enzyme (0.062 mg) and NADPH ( 0.1 mM) were 
added, and the reaction was allowed to proceed at 24 °C for 30 min.  The samples 
were then frozen, lyophilized, redissolved in water and loaded on a small Dowex1 
column. The resin was washed extensively with water, to remove any unbound 
radioactivity, and Ru5P was eluted with 4 x 0.5 ml of NaCl O.5 M.  The eluate was 
assayed for radioactivity and Ru5P. 
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Reverse reaction measurements  
 
The effect of isotope substitution on Ru5P in the reverse reaction was measured by 
comparing the relative reaction rates of the (1h) and (1d) Ru5P.  The reaction was 
carried out in O.1 M NaHCO3 saturated with CO2, pH 6.9, 0.1 mM NADPH, 1.24 µg 
of 6PGDH, measuring the decrease of the absorbance of NADPH.  Tritium isotope 
effect was measured in the same NaHCO3/CO2 buffer, pH 6.9, with 1mM NADPH, 
0.062 mg of 6PGDH, 5.0 mM isocitrate and 5 units of isocitrate dehydrogenase.  At 
the desired times 0.1 ml samples were withdrawn from the reaction mixture and 
loaded on a small Dowex1 column.  The column was washed extensively and Ru5P 
was eluted with 0.5 M NaCl, assayed and counted as described above. 
 
Data treatment  
 
Data were fitted with equation 1 and 2 for 1(1h)Ru5P and 1(1d)Ru5P respectively. 
 
v= VA/(KA+A)                                                        (1) 
v= VA/((KA(1+fiEV/K)+A(1+fiEV))                                            (2) 
 
where v and V are the initial and maximal velocity, KA is the Michaelis constant for 
the variable substrate, A is the concentration of the variable substrate, fi the fraction 
of deuterium label in the substrate, EV and EV/K the isotope effects minus 1 on V and 
V/K [74, 75]. 
T(V/K) was calculated from equation 3 at 10, 20 and 30% of substrate conversion: 
 
T(V/K) =log(1-f)/log[(1-f)ASt/AS0]                                            (3) 
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where ASt and AS0 are the specific radioactivity at time t and time 0 respectively, and 
f is the fraction of the substrate reacted. 
The overall kinetic equation is 
 
 
where A is NADPH, B Ru5P, C is CO2, P and Q are 6PG and NADP respectively. X 
stays for the enol form of Ru5P and K for the 3K6PG.  Accordingly to Northrop the 
isotope effects are 
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Intrinsic isotope effect was calculated from the equation: 
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PART I      RESULTS AND DISCUSSION 
 
 
Studies on the wt enzyme 
 
Substrate and inhibitor binary complexes 
 
The binding parameters for 6PG, 5PR and 4PE of T. Brucei 6PGDH wild type are 
reported in Table 3. The best fit of the average number of binding sites is slightly 
lower than two sites per dimer, reflecting the presence of some inactive enzyme. 
Although the observed Kd values for 6PG and 5PR are very close to their Km and Ki 
values, respectively, 4PE has a higher Kd value than the Ki value measured 
previously. The enthalpy change measured experimentally in titrations with 6PG 
arises primarily from the buffer protonation (Table 3); indeed, the release of 0.4 
hydrogen ions was calculated from measurements in different buffers. The buffer-
independent enthalpy change for the binding of 6PG is low and positive, 0.174 kcal 
mol-1, and the binding is totally entropy driven. 
The buffer-independent enthalpy change for the binding of 5PR and 4PE is negative 
(Table 3), with the release of only a small fraction of hydrogen ions (0.029 for 4PE 
and 0.018 for 5PR); however, for the substrate analogues also, the main contribution 
to binding comes from an increase in entropy. 
In all cases, the binding is entropy driven, and desolvation of the phosphorylated 
sugars appears to give the major contribution to the binding entropy. It has been 
shown that the binding of inorganic phosphate to the complex between porcine 
elastase and the turkey ovomucoid third domain has favourable entropy and 
unfavourable enthalpy as a result of the release of strongly immobilized water 
molecules [70]. Phosphorylated sugars should show a similar behaviour, and the 
major part of the entropy gain observed could arise from the phosphate group. 
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Furthermore, we observed that T∆S decreases by about 500–700 cal by shortening the 
carbohydrate chain for each carbon atom (Fig.15), probably reflecting the water 
molecules immobilized by hydrogen bonds with the sugar hydroxyl. Thus, the high 
entropy gain obtained by the desolvation of the ligands can overcome the entropy loss 
caused by the immobilization of the carbohydrate chain. 
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                                       6PG                       5PR                     4PE 
                                     Fig.15. Structures of 6PG, 5PR and 4PE. 
 
The enthalpy changes should also be discussed. The binding enthalpy for the 
inorganic phosphate to the elastase-ovomucoid third domain complex is about +3 
kcal mol-1. In this complex, there is only one ionic bond, whereas, in 6PGDH, the 
phosphate group of 6PG forms two ionic bonds with R289 (R287 in the sheep liver 
sequence, R289 in the Lactococcus lactis enzyme shown in fig. 16)  and R453 (R446 
in the sheep liver sequence, R447 in the L. lactis enzyme, fig.16). 
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                             Fig.16.Structure of L. lactis enzyme at the substrate binding site. 
 
It has been shown by site-directed mutagenesis of sheep liver 6PGDH that these two 
arginine residues can contribute to the binding free energy by -4.0 and -2.8 kcal* 
mol-1, respectively. Thus, the additional enthalpy gain generated by a second ionic 
bond could overcome the positive enthalpy change generated by desolvation of the 
phosphate group. 
 
Ligand Kd (µM) KmKi (µM) ∆H0(cal mol-1) T∆S0(cal mol-1) nH+ Sites/dimer 
6PG 4.96 ± 0.69 3.5 173.8 7398 -0.46 1.47 ± 0.06 
5RP 1.35 ± 0.19 0.95 -1330 6626 -0.018 1.33 ± 0.1 
4EP 2.86 ± 0.79 0.13 -2381 5111 -0.029 1.83 ± 0.3 
 
Table 3 Binding parameters of substrate and substrate analogues to 6PGDH from Trypanosoma 
brucei,  KmKi values are taken from [49,55]. 
 
-2.8 kcal/mol 
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Nevertheless, although the binding enthalpy of the inhibitors is negative, the binding 
enthalpy of 6PG is small and positive. This correlates with the proton release during 
binding (Fig.17).  
 
                                      Fig. 17. ITC titration with 6PG in two different buffer. 
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The fact that ∆Hobserved is higher in Tris buffer (red) than in Hepes (black) indicates 
that there is H+ release from the enzyme. 6PG releases about 0.4 H+, and this can 
account for up to 2–3 kcal mol-1 if the hydrogen ion is removed from a nitrogen acid. 
Both 5PR and 4PE release a very small amount of H+, and so the measured binding 
enthalpy is not shielded by the cost of proton release. The H+ release is observed only 
in the enzyme-6PG complex, indicating that some rearrangement of the enzyme 
occurs when the substrate binds, whereas inhibitors are not able to induce the same 
changes. The selective action of the substrate could be correlated with the change in 
the protonation state of Lys185, the residue involved in the catalytic activity, that is 
supposed to release H+ on binding of the substrate (Fig. 2). The hydroxyl group at C2 
of 5PR and the carboxylate group of 4PE (Fig.15) correspond to the hydroxyl group 
at C3 of 6PG, which faces the amino group of catalytic K185 (Fig.2). 5PR does not 
release H+, probably because it does not fit the active site in the same conformation of 
6PG; indeed, it has an inverted configuration at C2, so that the hydroxyl group could 
be misaligned to K185. 4PE does not release H+ either, probably because the 
negatively charged carboxylate group facing K185 requires a positively charged 
group (Fig.12). 4PE (and its derivative 4PEX) is a very powerful inhibitor of 
6PGDH, and it has been suggested that it might resemble the dienol intermediate. If 
4PE binds to protonated K185, the inhibitor resembles more closely the 3-keto 
intermediate, which has been suggested to be next to K185 in the protonated state 
(Fig. 12). As discussed below, 4PE strongly affects the binding of both NADP and 
NADPH, again suggesting that this inhibitor can mimic some features of the 3-keto 
intermediate. 
 
Enzyme–coenzyme complexes 
 
The binding parameters for NADP, NADPH and aPyADP (a nonoxidizing analogue 
of NADP, fig.18) are reported in Table 4. A binding isotherm and the fitted data for 
the binding of aPyADP to the enzyme are shown in Fig.19.  
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Fig.18. Structures of  NADP+ and 3-Amino pyridine adenine dinucleotide phosphate. 
 
 
 
 
Ligand Kd (µM) ∆H0(cal mol-1) T∆S0(cal mol-1) nH+ Sites/dimer 
NADP 7.54 ± 0.19 -5382 1486 -0.18 1.86 ± 0.13 
NADPH 1.05 ± 0.05 -11819 -3093 0.08 2.07 ± 0.05 
aPyADP 1.56 ± 0.1 -10581 -2838  0.45 1.65 ± 0.012 
 
Table 4. Binding parameters of coenzymes to 6PGDH from Trypanosoma brucei. 
 
 
The binding stoichiometry was close to two sites per dimer for all the coenzymes 
tested. A quite surprising result is the relatively high value of Kd for NADP, around 
an order of magnitude higher than the Km value of the coenzyme. 
P P 
NADP+ 3-Amino pyridine adenine dinucleotide phosphate 
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Fig. 19. Titration of T. brucei 6PGDH with aPyADP. The cell contained 5.2 µM dimer 
concentration in 50 mM Hepes buffer at pH 7.5, 0.1 mM EDTA and 1 mM 2-mercaptoethanol. The 
syringe contained 0.43 mM aPyADP in the same buffer. A total of 25 injections was made at 380 s 
intervals. Top panel: raw ITC data. Bottom panel: data after the subtraction of the control titration 
and peak integration. The full line is the fit to a single-site model. 
 
 
The enthalpy change for NADP binding is relatively low, and a positive entropy 
change contributes to binding. For NADPH and aPyADP, the binding appears to be 
totally enthalpic, and a negative entropy change is associated with complex 
formation. It is known that NADP and NADPH bind in a different way to sheep liver 
6PGDH. The differences in the thermodynamic parameters between oxidized and 
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reduced coenzyme suggest that, also in the T. brucei enzyme, coenzyme binding 
involves different interactions with the protein. 
With regard to the thermodynamic parameters, aPyADP resembles more closely 
NADPH, even though the amino-pyridine ring should be more similar in geometry 
and charge to that of NADP. Indeed, aPyADP has been used as an analogue of the 
oxidized coenzyme in 6PGDH from Candida utilis. The anomalous behaviour of 
aPyADP could result from the lack of the carboxamide group (Fig.18), allowing a 
conformation of the binary complex closer to that of the reduced coenzyme. The 
different conformation, and the lower steric hindrance, could slightly perturb the pK 
value of the ionizable groups surrounding the amino-pyridine moiety, resulting in the 
uptake of 0.45 H+. 
 
Half-site reactivity of ternary complexes 
 
 
Titration of the enzyme-6PG complex with aPyADP (Fig. 20) shows a small increase 
in the dissociation constant of the coenzyme analogue, a more negative binding 
enthalpy and, more interestingly, a decrease in the binding stoichiometry of the 
coenzyme (Table 5). 
 
Titrant Binary complex Kd (µM) ∆H0(cal mol-1) T∆S0(cal mol-1) Sites/dimer 
aPyADP 6PGDH-6PG 3.62 ± 0.27 -12645 -5467 1.07 ± 0.08 
NADPH 6PGDH-6PG 2.04 ± 0.58 -15670 -8000 1.55 ± 0.064 
 NADP 6PGDH-5PR 12.9  ± 3.38 -18599 -12273 0.879  ± 0.013 
 NADP 6PGDH-4PE 0.043 ± 0.04 -15742 -6010 1.0 ± 0.003 
 NADPH 6PGDH-4PE 0.0203 ± 0.0103 -22299 -12089 1.58  ± 0.09 
 6PG 6PGDH-aPyADP 10.2  ± 0.7a ND ND ND 
 4PE 6PGDH-NADP 0.177 ± 0.015 
1.62 ± 0.062 
-8741 
-2232 
285.6 
5601 
1.0 ± 0.1 
1.0 ± 0.1 
 
Table 5 Ternary complexes of 6PGDH from T. brucei. ND, not determined. 
              
a
 From the fluorescence measurements. 
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Fig. 20. Titration of the Trypanosoma brucei 6PGDH-6PG complex with aPyADP. The cell 
contained 5.2 µM dimer concentration and 1.2 mM 6PG in 50 mM Hepes buffer at pH 7.5, 0.1 mM 
EDTA and 1 mM 2-mercaptoethanol. The syringe contained 0.43 mM aPyADP and 1.2 mM 6PG in 
the same buffer. A total of 25 injections was made at 380 s intervals. Top panel: raw ITC data. 
Bottom panel: data after subtraction of the control titration and peak integration. The full line is the 
fit to a single-site model. 
 
Indeed, only one coenzyme molecule per enzyme dimer is bound. Titration of the 
same enzyme-6PG complex with NADPH gives a stoichiometry of 1.55 coenzyme 
molecules per dimer, a value similar to that observed in binary complexes, which 
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could be accounted for by the partially inactivated enzyme. Thus, the differences 
between aPyADP and NADPH binding reflect a real change in the stoichiometry. 
Titration with NADP of the binary complexes of the enzyme with the inhibitors 5PR 
or 4PE again shows a binding stoichiometry of about one coenzyme molecule per 
dimer, confirming the presence of half-site reactivity. Likewise, for 4PE, the binding 
stoichiometry of NADPH is 1.58 coenzyme molecules per dimer, indicating that the 
half-site reactivity is strictly limited to the oxidized coenzyme. 
To test whether the half-site reactivity involves only the coenzyme, or both NADP 
and substrate, 6PGDH was titrated with 6PG and 4PE in the presence of saturating 
concentrations of aPyADP and NADP, respectively. The titration of the enzyme–
aPyADP complex with 6PG gives small signals, whose values are so close to blank 
titrations that it is impossible to handle the experimental data. As binding 
stoichiometry suggests that only one coenzyme molecule per dimer is bound in the 
ternary complex, titration of the enzyme-(aPyADP)2 complex with 6PG should cause 
the release of a coenzyme molecule from the dimer (Fig. 21, step 4). aPyADP release 
has a large positive ∆H value and is accompanied by H+ release (Table 4). 6PG 
binding has a small positive ∆H value and is accompanied by H+ release (Table 3). 
Thus, during the formation of the enzyme-6PG-aPyADP ternary complex from the 
enzyme-(aPyADP)2 complex, there are two opposite effects: a positive ∆H value for 
aPyADP release and 6PG binding, and a negative ∆H value for buffer protonation. 
These opposite effects can result in an experimental value close to blank data. 
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Fig. 21. Kinetic mechanism of the binding to 6PGDH of the substrate 6PG and the NADP analogue 
aPyADP. The enzyme is a homodimer with a NADP half-site reactivity in the presence of 6PG. 
 
To further study the binding of 6PG to the enzyme-aPyADP complex, we measured 
the changes in the fluorescence of the bound coenzyme on addition of 6PG (Fig. 22). 
The fluorescence changes cannot be fitted with a simple binding isotherm; however, 
the data are consistent with the mechanism depicted in figure 15, where the substrate 
does not bind to the enzyme-(aPyADP)2 complex. The resulting Kd value, 10.2 ± 0.7 
µM (Table 5), is close to 7.81 µM, the value calculated on the basis of multiple 
equilibrium constraints: 
 
K6PG4 = K6PG1 KaPyADP2/KaPyADP3  
 
where the numbers in the subscripts refer to the steps in Figure 21. 
Further support for the half-site model for T. brucei 6PGDH comes from enzyme 
kinetics. Indeed, although at high 6PG concentrations the enzyme displays the usual 
Michaelis-Menten kinetics towards NADP, at low 6PG concentrations the enzyme 
shows a marked inhibition by NADP (Fig.23). 
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Fig. 22. Fluorescence titration of the 6PGDH–aPyADP complex with 6PG. Changes in the 
fluorescence of the bound coenzyme on addition of 6PG are shown. Lines were obtained by 
nonlinear least-squares fitting to a full-site model (broken line) or a half-site model (full line). 
 
 
Fig. 23. Inhibition of T. brucei 6PGDH by NADP. The assay mixture contained 1 mL of 50 mM 
triethanolamine buffer, pH 7.5, 1 mM EDTA, 1 mM 2-mercaptoethanol, NADP at the concentration 
indicated on the abscissa and either 20 µM 6PG (open circles) or 2.2 mM 6PG (filled circles). 
 
This substrate-dependent inhibition by the coenzyme has been observed previously 
for the enzyme from C. utilis, and has been correlated with the presence of half-site 
reactivity. At low substrate concentrations, the coenzyme inhibits the enzyme by 
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shifting the equilibrium towards the non productive enzyme-(NADP)2 complex that 
cannot bind the substrate. At high substrate concentrations, the equilibrium is shifted 
towards the enzyme–substrate complex, preventing the binding of the second 
coenzyme molecule, and the inhibition is cancelled [36]. 
In conclusion, titration of the enzyme-aPyADP complex with 6PG [by both 
isothermal titration calorimetry (ITC) and fluorescence measurements], titration of 
the enzyme-6PG complex with aPyADP and kinetic data all support the half-site 
reactivity of T. brucei 6PGDH, where only one ternary complex can be formed on the 
enzyme dimer. 
The binding of 4PE to the enzyme-(NADP)2 complex gives a large measurable 
enthalpy change, and the best fit is obtained by assuming two sequential binding 
sites. The first site shows an apparent Kd value of 0.177 µM, very close to the Ki 
value of the inhibitor determined kinetically (0.18µM) [49]. However, K2 in Figure 
21 must be given by the product K3K4 ⁄K1, which is 0.015 µM, much lower than the 
measured Kd value. To explain this discrepancy, it should be considered that only one 
NADP molecule can be present in the ternary complex (Table 5), so that, in the 
formation of the ternary complex, the excess of NADP could act as a competitive 
inhibitor of 4PE (Figure 21, step 5). In other words, NADP could act as an inhibitor 
for 4PE binding in the same way as NADP inhibits enzymatic activity. If this holds 
true, the Kd value measured experimentally is an apparent dissociation constant, and 
the true value should be obtained by correcting the experimental value by the usual 
term Kapp= Kd(1 + [I] ⁄Ki), where I is NADP and Ki is the dissociation constant of 
NADP for the free enzyme. In our experimental conditions, the calculated true Kd 
value is 17.7 nM, in good agreement with the value imposed by multiple equilibrium 
constraints. 
The second site shows Kd and ∆H values close to those of the binary complex, 
suggesting that the asymmetric form of the enzyme causes only moderate effects on 
the substrate binding site of the subunit devoid of the coenzyme. Thus, the 
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asymmetric ternary complex binds only one NADP molecule, but still binds two 
substrate molecules. 
The half-site reactivity of 6PGDH has been observed previously in the enzyme from 
C. utilis and from sheep liver. In both cases, the evidence was obtained using an 
inhibitor derived from NADP, periodate-oxidized NADP [29,30]. Further support for 
an asymmetric functional enzyme has been obtained by studying the binding of 
aPyADP in the presence of 6PG [36], and by observing that 6PG enhances the 
decarboxylation of 3-keto-2-deoxy 6PG, an analogue of the putative intermediate 3-
keto 6PG [65,34,35]. Recently, the crystallographic structure of the ternary complex 
of L. lactis 6PGDH with NADP and 4PEX⁄4PEA has been published, showing only 
one subunit filled by both coenzyme and inhibitor [27]. The superimposition of the 
subunit bearing NADP and the inhibitor on the other subunit shows a movement of 
the cofactor binding domain, resulting in a 5° rotation and a 0.7 Å translation, 
indicating a structural change on one subunit when the other is filled by the ternary 
complex [27]. 
Here, we have shown by direct binding experiments that 6PGDH from T. brucei also 
makes only one ternary complex per dimer. In conclusion, the half-site reactivity 
appears to be common behaviour for 6PGDH. 
 
Substrate analogues and transition state analogues 
 
 
The ternary complexes formed by aPyADP and 6PG or NADP and 5PR are very 
similar. Indeed, although the binding enthalpy of the coenzymes is higher in ternary 
complexes than in binary complexes, the enthalpic gain is compensated by a large 
entropy loss, and Kd changes slightly (Tables 4 and 5). The large entropy decrease 
could be a consequence of the tighter binding that reduces the conformational 
freedom of the residues interacting with the ligands [66]. 
The fact that the Kd value of 5PR is close to the inhibition constant (Table 3) suggests 
that 5PR is simply a substrate-competitive inhibitor. 
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Quite different behaviour is observed for the ternary complexes with 4PE, where the 
Kd values of NADP and NADPH show a dramatic decrease. In these complexes, the 
enthalpy gain overcomes the entropy loss as a result of the tighter binding. 
In L. lactis 6PGDH, an overlay of 4PEX with 6PG and Ru5P indicates that the 
inhibitors adopt similar conformation in the active site [27]. However, 4PEX lacks 
the three hydrogen bonds formed by the carboxylate group of 6PG; nevertheless, the 
Ki value is far below the Kd value of the substrate. The very tight binding of 4PEX 
can be explained by suggesting that the planar nature of the hydroxamate group 
should mimic the planar structure of the dienol intermediate (Fig. 21). It is reasonable 
that 4PE adopts a conformation similar to that of 4PEA, with a water molecule 
bridging the carboxylate O1 to the catalytic E192 [27,54](Fig. 24). 
 
                                          
 
Fig.24.  Model of the 4PE bound at the active site of T. brucei 6PGDH, with only the amino acid 
residues Lys 185 and Glu 192 shown, based on the reported structure model of the complex of L. 
lactis 6PGDH with PEA [54].  
 
The observation that 4PE strongly affects both NADP and NADPH binding suggests 
that the inhibitor should mimic an intermediate in the dehydrogenation step, where 
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the coenzyme structure changes from the oxidized to the reduced form (Fig. 12). 
Deuterium kinetic isotope effects indicate a non symmetric transition state for the 
dehydrogenation reaction, suggesting a ‘late’ transition state [67]. Within this 
hypothesis, K185 goes from the non protonated form in the reagents to the protonated 
form in the transition state, together with C3 becoming planar. The negative charge of 
the carboxylate group of 4PE could force K185 into the protonated form, thus 
supporting the conformational⁄charge changes that strengthen the binding of the 
transition state. 
We suggest that 4PE and 4PEX represent the transition state analogues of two 
different steps: 4PE, dehydrogenation; 4PEX, decarboxylation (Fig. 12). 
The results presented here show some important features fruitful for the design of 
inhibitors specific for T. brucei 6PGDH. 
The first observation focuses attention on the role of entropy and the phosphate 
group. The major contribution to the binding energy of 6PG and its analogues comes 
from entropy and, in particular, from the entropy gain resulting from the desolvation 
of the phosphate. The bonds formed by the ligand with the enzyme can only 
counterbalance the positive desolvation enthalpy of the phosphate. Therefore, the 
design of new inhibitors should firstly preserve the entropy gain. 
The second observation is on the proton linkage, an aspect that can escape the 
analysis of crystallographic structures. Both the proton release and internal 
rearrangement of the ionic charges can affect negatively the binding enthalpy. By 
comparing the binding enthalpy of 6PG and 4PE, it appears that, despite 4PE forming 
a smaller number of hydrogen bonds than 6PG, the binding enthalpy is greater. This 
can be related to the absence of H+ loss on binding of the inhibitor. The presence of 
the charged carboxylate anion of 4PE near K185 strongly suggests that this residue 
must be charged, whereas the catalytic mechanism requires an uncharged lysine in 
the complex with 6PG. The transfer of a hydrogen ion from K185 to the medium or 
to another functional group of the protein could have a high energy cost, which is 
absent in the binding of the inhibitor. This appears to be the most rational explanation 
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of the high affinity of 4PE. Therefore, a better understanding of the catalytic 
mechanism is a prerequisite for the correct design of new inhibitors.  
Last, but not least, the transition state involves not only the substrate analogue, but 
also the coenzyme. In other words, the inhibitor must be more efficient when the 
coenzyme is present. In the case of 4PE, the Kd value of the inhibitor is close to the 
Kd value of the substrate, but it decreases by two orders of magnitude in the presence 
of both oxidized and reduced coenzyme. This means that a powerful inhibition occurs 
under both normal cellular conditions, when the NADPH/NADP ratio is high, and 
stress conditions, when NADPH decreases and NADP increases. 
 
 
Studies on site-directed mutants of T. brucei  6-PGDH 
 
 
As reported in the Introduction section, K185 and E192 (K183 and E190 in the 
sl6PGDH) appear the residues directly involved in the catalysis. These residues have 
been identified from the 3D structure of the sheep enzyme and from site-directed 
mutagenesis. The sheep liver enzyme shows the typical bell-shaped activity-pH 
curve, while the K182R mutant looses the high pK, and the E190Q looses the low pK 
[16,17]. Thus it was concluded that the bell-shaped curve comes from the ionization 
of the two residues. However, when these data were published, the same experiments 
with the Tb6PGDH were in progress in our laboratory, and the results were quite 
different.  For this reason we have reinvestigated not only the kinetics of the mutants 
of Tb6PGDH, but also we tried to verify the substrate-induced change in the 
ionization of the two residues as postulated by the reaction mechanism. 
At the beginning three mutants were studied: K185R where lysine is replaced by a 
more basic residue as arginine, K185H where lysine is replaced by a more acid 
residue as histidine, and E192Q where the charged glutamate is replaced by a neutral 
residue as glutamine. Kinetic parameters at pH 7.5 are reported in table 6.  
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         Table 6. Kinetic parameters of mutants (E192Q, K185R and K185H) and wt enzyme. 
 
For the K185H it was not possible to obtain Km values for the substrate and the 
coenzyme since it has a bi-phasic kinetics and kinetics is not linear at low substrate 
and coenzyme concentration. All mutations reduced the enzyme oxidative activity by 
at least three orders of magnitude, indicating that K185 and E192 are really two key 
residues in the 6PGDH activity. Km values both for 6PG and NADP increase in the 
mutants compared to the wt. In fig.25 their pH curves are reported together with the 
wt one and the pKs obtained from the pH curves are reported in table 7.    
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Fig.25. Activity-pH curves. The Y scale is multiplied by an arbitrary factor to  allow comparison of  
the mutant logV with the WT one.  
 
 
  Wild Type E192Q K185R K185H 
A.S.(UI/mg) 30 0.028 0.02 0.032 
Km 6PG (uM) 3.5 12 10.6 // 
Km NADP (uM) 1 4.5 7.1 // 
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                                                  Table 7. pK of  K185R, E192Q and wt 
 
The wt pH curve has the typical bell shape, consistent with the ionization of two 
residues with pK of 6.6 and 9.8, which, as suggested for the sheep liver enzyme, 
should be of the glutamate and the lysine. The T. brucei mutant curves show a more 
complicated picture, not similar to that observed for the sheep enzyme, where the 
lysine or the glutamate mutation causes the loss of one of the two pKs, leaving save 
the other one. In the T. brucei 6PGDH both pKs are perturbed both in the K185R 
mutant and in the E192Q one. For the K185R the first pK is shifted by 1.2 units 
toward high pH, while the second pK is down shifted by 1.65 pH units.  These data 
are clearly incompatible with the assumption the higher pK (9.8) observed in the pH 
curve is the pK of the K185. The same conclusion can be attained for the E192Q, 
where the first pK is down shifted by 1.7 pH units, and the second pK is up shifted by 
2.2 pH units. In conclusion while K185 and Q192 heavily affect the pH curve, other 
residues are involved.   
These results clear the oversimplified model of the pH curve, and open the way to the 
search on the origin of the shape of the pH curve, whether it comes from other 
residues involved in the catalytic activity, or from a “global” rearrangement of 
several unrelated residues induced by conformational changes. 
A second question, arising from the experiments on K185R and E192Q mutants, is if 
the substrate-induced change in the ionization of the two residues postulated by the 
reaction mechanism is correct.  
Two ionisable residues, conserved in all 6PGDH, and not directly involved in the 
contact with the substrate but within 10 Å of the active site, are H188 and C372. 
 pKa1 pKa2 
WT 6.6 9.8 
K185R 7.8 8.15 
E192Q 4.9 12 
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Two mutants of these residues were prepared, H188L (where histidine is replaced by 
leucine, a residue with approximatively the same steric hindrance but devoid of acid-
base property) and C372S (where cysteine is replaced by an analogue not ionizable 
residue as serine) to assay the role of H188 and C372. 
Residual activity of the H188L mutant is the 4% of the wt while is 50% for the 
C372S (Table 8), while their pH curves (Fig. 26) present alteration of one of the two 
pKs, the acid for H188L and the basic one for C372S (Table 9).  
 
 
 
 
 
                 
            Table 8. Kinetic parameters of mutants (H188L and C372S) and wt enzyme. 
                           N.d. not determined. 
 
     
 
 
 
 
 
 
 
 
 
 
Fig.26. Activity-pH curves. The Y scale is multiplied by an arbitrary factor to allow comparison of 
the mutant logV with the WT one.  
 
 
 
  Wild Type H188L C372S 
A.S.(UI/mg) 30 1.31 16 
Km 6PG (µM) 3.5 300 42 
Km NADP (µM) 1 n.d 21 
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                                                 Table 9. pK of H188L, C372S  and wt. 
 
The relatively small decrease of specific activity, in particular for C372S, is 
consistent with a secondary role of these residues in the catalysis. However the 
changes in the pH curves requires some comments. 
The pH curve of the mutant H188L is nearly superimposable at high pH, where the 
histidine is neutral, while it shows a shift of about 0.4 units at low pH, where the 
histidine bears a positive charge. This suggests that H188 decreases the pK of some 
residue(s) contributing to the first pK of the pH curve.  In a similar way the curve of 
the mutant C372S is nearly superimposable at acidic pH, where the cysteine is 
expected to be neutral, while it shows a shift of about 0.8 units at high pH, where the 
cysteine bears a negative charge. This suggests that C372 decreases the pK of some 
residue(s) contributing to the second pK of the pH curve. 
These results suggest that the pK observed in the pH curve cannot be attributed to 
H188 or C372, despite these residues have a role in determining the exact value of 
the pKs.  
It is noteworthy that also the sl6PGDH mutants show a very similar behaviour 
(Fig.27).  
 pKa1 pKa2 
WT 6.6 9.8 
H188L 6.95 9.6 
C372S 6.7 9 
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Fig. 27. Activity-pH curves in the sheep liver 6PGDH. The Y scale is multiplied by an arbitrary 
factor to allow comparison of the mutants (C365S and H186A) logV with the WT one.  
 
 
The pH curve of the H186A mutant is perturbed only at the acidic side of the curve 
[69], while the C365S mutant is perturbed only at the basic side of the curve 
(Cervellati, personal communication). However there are significant differences 
between the sl and Tb enzymes. The residual activity of H186A is significant (about 
15% of the native enzyme), while the residual activity of C365S is only 4%. Also in 
the pH curve it should be noted that for the H186A mutant the acidic pK is 
downshifted, while for the corresponding H188L mutant of the Tb6PGDH the acidic 
pK is upshifted. The different behaviour could result from the different steric 
hindrance in the two mutants. Nevertheless these two residues are involved in the 
conformational/ionization changes occurring at the substrate binding. 
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Hydrogen ion movements accompanying the 6PG binding 
 
The proposed reaction mechanism requires that the binding of the substrate changes 
the ionization state of the two essential residues, K185 and E192, with K185 loosing 
a H+ that is taken by E192.  To verify this hypothesis we measured by ITC the proton 
release/uptake occurring on the binding of the substrate. 
We firstly studied the wt and three mutants: K185H, K185R, and E192Q. Table 10 
collect data regarding H+ exchange between the enzymes and the medium and the 
∆H0 values. 
 
 
 
 
 
 
 
  Table 10. H+ exchanged between the enzymes and the medium and the ∆H0 values at pH 7.5. 
 
The wild type 6PGDH upon 6PG binding releases about 0.5 hydrogen ions at all the 
pH tested (6.5, 7.5 and 8.5), as reported in the previous part of the thesis (fig. 17). 
The observation that H+ release is pH independent rules out the contribution of the 
phosphate group of the substrate to the proton release.  
The titration of K185R mutant is indistinguishable from blank titrations at all pH, 
meaning that the mutant does not exchange H+ and that the binding enthalpy is zero. 
The K185H mutant at pH 6.5 releases about 0.5 H+, like the wt enzyme, while at pH 
7.5 and 8.5 the titration in different buffers show that at the formation of enzyme-
6PG complex there is capture of hydrogen ions by the medium. Thus at pH 6.5, 
where the histidine is protonated, there are no differences between wt and mutant 
enzymes, while at higher pH, where the histidine is uncharged, the difference 
Enzyme n° H+  ∆H0  Kcal/mole 
WT -0.4 ± 0.02  0.174 ± 0.02 
K185H 0.78 ± 0.015 -10.08 ± 0.015 
K192Q -1.5 ± 0.023       6.7 ± 0.023 
K185R 0 0 
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between wt and K185H mutant is about one hydrogen ion. This suggests that a 
hydrogen ion coming from the residue 185 is taken up by another enzyme residue. It 
is noteworthy that for K185H at pH 7.5 the buffer-independent binding enthalpy, 
∆H0, is negative. 
If the proposed mechanism is correct, the proton released by K185 should be taken up 
by E192. In fact the E192Q mutant releases a number of H+ greater than the wild type 
enzyme at pH 7.5. At pH 8.5 the mutant is unstable and precipitate during the 
experiment, so at this pH it was not possible to obtain results. For this mutant the 
value of ∆H0, is positive. 
The calorimetric experiments show that the wild type enzyme releases 0.4 H+ upon 
6PG binding. These hydrogen ions can be the result of two different phenomena:  1) 
an incomplete transfer of only part of the H+ coming from the lysine to the glutamate 
with the other released in the medium, or 2) a conformational modification that 
change the pKa of other ionization groups. 
The E192Q mutant brings to exclude the first hypothesis. At pH 7.5 this mutant 
release 1.49 H+ (Fig. 28), that is one hydrogen more than wild type. This means that 
the proton transfer of the lysine to glutamate is complete, and the binding of substrate 
causes structural modification bringing to release of 0.4 protons. 
The stoichiometry of the K185H mutant confirms this interpretation. In fact the 
K185H at pH 7.5, when histidine is non protonated, take 0.78 hydrogen ions. As the 
histidine pKa is about 6.9, at pH 7.5 the K185H should be in the protonated form for 
nearly 20%, thus if only a fraction of hydrogen ions should be transferred to the 
glutamate, the number of H+ taken from the medium should be lower than 0.3-0.4. 
The fact that K185H take up 0.78 (Fig. 28) suggests that the proton transfer from 
lysine to glutamate is complete. In conclusion the calorimetric data show that at the 
formation of the enzyme-substrate complex, the lysine transfer its proton to glutamate 
(Fig. 28), at the same time a structure rearrangement on the enzyme causes a release 
of  0.4- 0.5 protons. In this second process other residues can be involved, the same 
responsible of the pH effect on the enzyme activity. 
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Fig. 28. Scheme of the protonation change in residues 185 and 192 of the wild type enzyme and 
mutants E192Q and K185H. 
 
 
The solvent independent binding enthalpy of the three enzymes, wt, K185H and 
E192Q are very different, however if the binding enthalpies are corrected for the 
ionization costs, the true binding enthalpy appear very similar in all the enzymes. In 
fact the ionization enthalpy of a lysine or a histidine is about 7-8 kcal mol-1, while the 
ionization enthalpy of a glutamate is about 1-2 kcal mol-1. If also the hydrogen ion 
coming from the conformational transition comes from a nitrogen acid, this will add 
7-8 kcal mol-1. Taking these values, and the stoichiometry of proton release/uptake, 
the calculated binding enthalpy for all three enzymes ranges from 8.3 kcal mol-1 for 
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the wt, to 7.6 kcal mol-1 for the E192Q. These values are very close, and represent the 
true energy of the bonds between the enzyme and the substrate. However in the wt 
the overall binding energy is less than 0.2 kcal mol-1, while the remaining energy is 
spent in building up the catalytic machine. 
The evidences for a conformational change of the wt enzyme, with the release of 
about 0.5 H+, let us to investigate the other two mutants; H188L and C372S, to verify 
whether the moderate effect of these mutation on the enzymatic activity is correlated 
with the catalysis or with the conformational change. 
The binding of 6PG to the H188L mutant show similar ∆H0 in several buffers and the 
release in the medium of a very small amount of H+, about 0.08 (Table 11). This 
could mean either that the 0.46 H+ released by the wt come from the H188, or that the 
mutation of this residue impairs the conformational change reducing the enzymatic 
activity. As reported in the Introduction section, there are several evidences of a 
partially rate limiting conformational change of the enzyme-6PG complex, 
suggesting that the enzyme is shifted from an "open" to a "closed" form (Fig. 29). 
Kinetic isotope effects of the histidine mutant of the sl6PGDH suggest that this 
residue is involved in the conformational change induced by 6PG. Thus it appears 
more likely that the lack of proton release observed in the H188L mutant could be 
due to an impairment of the conformational change. 
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NAPH
E NADP
6PG+ 6PG
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3K6PG
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+
 
 
                 Open form              Closed form 
        
  Fig. 29. Isomerisation of the 6PGDH of T. brucei enzyme. 
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   Table 11: H+ exchanged between the enzymes and the medium and the ∆H0 values at pH 7.5. 
 
The C372S mutant release 0.23 proton (Table 11), about one half of the wt, and also 
the activity is one half of that of wt. Thus we verified whether there is a correlation 
between the number of H+ released and the specific activity. 
In figure 30 it is shown a correlation between proton release and enzyme specific for 
4 enzyme species: wt, K185R, H188L and C372S. 
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 Fig.30. Correlation  between proton release and enzyme specific activity, where • is  K185R,  ▲is 
H188L, ■ is C372S and   is wt. 
 
Enzyme specific activity and proton release correlate well only for these 4 species 
while K185H and E192Q, which show a 0.8 H+ uptake and a 1.5 H+ release 
Enzyme n° H+  ∆H0  Kcal/mole 
WT - 0.4 ± 0.02  0.174 ± 0.02 
H188L - 0.08 ± 0.016 
- 2.9±0.013 
C372S -0.23 ± 0.01 
- 1.5±0.012 
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respectively, do not correlate. This could well be expected since for these two 
mutants the proton release/uptake is related to the H+ transfer from K185 to E192, 
while for H188L and C372S the change in the H+ release is due to the impaired 
conformational change upon 6PG binding.  
 
Cysteine reactivity  
 
The conformational changes induced by 6PG binding cause several effects on 
6PGDH: increased stability to heat, denaturants, proteolysis, and a dramatic reduction 
of the reactivity toward chemical modifications. One of the best characterised effects, 
observed in 6PGDH from several sources, is the loss of reactivity of cysteine 
residues. Thus we have measured the effect of 6PG on the reactivity of the Tb 
6PGDH mutants. 
In the T. brucei wild type 6PGDH, three cysteines for subunit are fastly titrated by 
DTNB a pH 7.5, but in presence of 6PG one cysteine alone is titrated in more than 10 
minutes (Fig.31). In absence of 6PG one cysteine is also more reactive than the 
others. This behaviour seems in agreement with an open form of the enzyme and a 
closed more rigid form in the presence of 6PG. 
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              Fig. 31. Cysteine reactivity in the T. brucei  6PGDH in presence and absence of 6PG. 
 
This phenomenon has been observed in different species, and in the sheep liver 
enzyme the most reactive cysteine is cysteine 365 (Cervellati, not published data).  
This cysteine (cys 372 in the T. brucei enzyme) is conserved in all 6PGDHs, and is 
within 10 Å of the active site. For this reason its ionization, and its reactivity, can be 
correlated to the ionization state of the residues in the active site. 
In the wild type, the reactivity of the most reactive cysteine decreases 10-fold in the 
presence of 6PG (Fig.32). 
In the mutant E192Q there is a reduction of reactivity, comparable with that of the 
wild type in the presence of 6PG (Fig.32). 
The mutants of the lysine have a different behaviour, in the K185H mutant the 
cysteine reactivity is reduced compared to the wild type both in presence and absence 
of 6PG, while in the K185R mutant the cysteine reactivity is high in both cases, that 
is does not change in the presence of 6PG. These data suggest that the 372 cysteine 
reactivity depends on the ionization state of the residue 185: the cysteine is more 
reactive if the residue 185 is protonated, while the reactivity decreases if the lysine 
185 is not protonated, as it is supposed in the presence of the substrate. The K185H 
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mutant at pH 7.5 is not protonated even in absence of 6PG, since the pKa of the 
histidine is 6.9 and in this condition the cysteine reactivity is low. In the K185R 
mutant, for its higher pKa the arginine is not unprotonated, in the presence of 6PG 
too. However for K185H and E192Q the proton inventory indicates that, like in the 
wt, the 0,5 H+ are released in the medium, suggesting that the substrate is able to 
induce the correct conformational change. 
The cysteine reactivity in the C372S and H188L mutants is still high also in the 
presence of 6PG (Fig. 32) showing that the presence of the two residues C372 and 
H188 is critical to the shift of the enzyme form the "open" to the "closed" form. Also 
the K185R mutant, that does not exchange hydrogen ions with the medium, shows 
the high reactivity of the cysteine residues suggesting an "open" conformation. 
 
 
Fig. 32. The cysteines reactivity in absence and in presence of 6PGDH for wild type, H188L and 
C372S. 
 
The initial reaction rates of the cysteine in the presence of 6PG were plotted against 
the activity of the different mutants (Fig. 33). As already observed for the proton 
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release, also the reactivity of the cysteines correlates with the activity, suggesting that 
the loss of activity of the H188L and C372S is due to an impairment of the 
conformational transition required to put the enzyme in the correct catalytic 
conformation. 
Thus even if H188 and C372 are not directly involved in the substrate binding, they 
have an important role in the rate-limiting shift of the 6PGDH conformation from the 
"open" to the "closed" catalitically active form (Fig. 33). 
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Fig. 33. Initial reactivity of the cysteine residues in the enzyme-6PG complex, where ■ is wt,  is 
C372S, • is H188L and ▲is K185R. 
 
The decrease of enzymatic activity of Tb 6PGDH mutants appears to correlate both 
with the reduced protection of cysteine residues by substrate, and with the number of 
hydrogen ions released upon substrate binding. This strongly suggests that the 
substrate induced conformational change plays a key role in the enzymatic activity, as 
already suggested by kinetic isotope effect studies. Although several residues could 
be involved in this conformational change, some hypothesis can be drawn on the role 
of the residues here studied. 
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As noted above, H188 and to lesser extent C372 are required for a correct 
conformational transition. However also the K185 mutants appear to have a key 
function in the transition. In fact K185R does not releases hydrogen ions and does not 
show 6PG protection of the cysteine residues, meaning that it is unable to allow the 
transition from the "open" to the "closed" conformation. A closer examination of the 
K185H suggests that also this mutation affects the conformational change.  In fact in 
K185H the hydrogen ion taken by E190 comes from the solvent (about 0.8 H+) and 
from the residual charge of H185 (about 0.2 H+), meaning that the binding of 6PG 
does not cause the release of H+ related to the conformational change. However 
K185H shows a very low reactivity of the cysteine residues, similar to that of the wt 
enzyme-6PG complex, both in the presence and in the absence of 6PG, suggesting 
that this mutant is in a conformation similar to the "closed" one also in the absence of 
the substrate. 
 
The binding of 6PG to the Tb 6PGDH involves a large energy change, and the 
enthalpy contribution to the binding is spent in transferring a hydrogen ion from 
K185 to E190, and in a conformational change required to put the enzyme in the 
catalytically competent conformation. This conformation requires that the residue 
185 should be uncharged, as suggested by the different behaviour of K185H and 
K185R. Other residues, H188 and C372, are at different extent involved in the 
conformational change. The catalytically active conformation is probably retained 
until the end of the reaction, in fact the complex with the transition-state analogue 
4PE shows the same reactivity of the cysteine residues observed in the enzyme-6PG 
complex, and the catalytic mechanism suggests a charged K185, and proton inventory 
data are consistent with the retention of the hydrogen ion on K185.  
The conformational transition induced by 6PG is a prerequisite for the further 
conformational changes that affect the coenzyme binding site. In fact in the presence 
of 6PG the enzyme shows the half-site reactivity toward NADP+. The relevance for 
the catalytic mechanism of the change from the half-site conformation to the full site 
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conformation is still elusive. In fact 4PE, that shows all the features of a reaction 
intermediate, induces half-site reactivity with NADP+ but full site reactivity with 
NADPH.  
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PART  II 
 
The reverse reaction of 6PGDH studied by kinetic 
isotope effects  
 
Hydrogen exchange between Ru5P and water 
 
The kinetic mechanism of the reverse reaction of 6PGDH can be described as follow: 
 
were A is NADPH, B Ru5P, C is CO2, P and Q are 6PG and NADP respectively. X 
stays for the enol form of Ru5P and K for the 3K6PG. 
Two enzyme isomerisation steps, k3 /k4 and k11/k12 have been inferred on the basis of 
the results reported below (k3/k4) and on the published data (k11/k12) [74,75]. 
 The first step of the reductive carboxylation of Ru5P to 6PG catalysed by 6PGDH is 
the conversion of Ru5P into a dienol, with the release of the proR hydrogen of Ru5P.  
This reaction requires the presence of NADPH but occurs even in the absence of 
CO2, and the hydrogen is exchanged with the medium [14,76] .  Therefore we firstly 
studied the kinetic isotope effects on the exchange reaction. 
We measured the rate of hydrogen exchange between Ru5P-1-h and Ru5P-1-d and 
tritiated water. The rates of tritium uptake were 0.128±0.004 µmoles min-1 mg-1  for 
Ru5P-1-h and 0.131±0.004 µmoles min-1 mg-1 for Ru5P-1-d, with a vH/vD 0.98±0.06. 
Furthermore the rate of tritium release from Ru5P-1-t, 0.129±0.06 µmoles min-1 mg-1, 
is the same of the tritium uptake from Ru5P-1-h. The vH/vD ratio is very close both to 
unity and to the equilibrium isotope effect. This means that C-H breaking is not rate 
limiting and either deuterium (or tritium) equilibrates freely with the solvent or the 
EAC + B           EABC            E’ABC           EAX              EAK           E’PQ           EPQ              E+P+Q  
k1 k3 
k2 k4 
                    
k5 
k6 
k7 
k8 
k9 
k10 k12 
k12 k11 
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hydrogen ion is shielded from the solvent and the exchange is a side reaction not 
affected by the isotopic substitution. 
The rate of tritium release is low and increases by about one order of magnitude when 
measured in the reverse reaction.  This suggests that either the hydrogen exchange is 
a side reaction or the presence of CO2 increases the rate of hydrogen release from 
Ru5P. To verify whether CO2 plays a direct role in the proton abstraction from Ru5P, 
we studied the rate of tritium exchange in the presence and in the absence of CO2 by 
using as coenzyme the 1,6NADPH, a non-reducing analogue of NADPH. This 
analogue can replace the natural coenzyme in the tritium exchange and in the 
decarboxylation [73]. Our experiments show that the presence of CO2 does not 
modify the rate of tritium release from Ru5P-1-t, ruling out any role of CO2 in the 
first step of the reaction.   
The low rate of hydrogen exchange in the absence of the full reverse reaction, and the 
lack of isotope effect observed in the exchange reaction, both suggest that this is a 
side reaction that cannot modify at significant extent the isotopic composition of 
Ru5P during the measurements of the isotopic effects on the reverse reaction. 
 
Kinetic isotope effects on the reductive carboxylation. 
 
The tritium isotope effect on the V/KRu5P in the reverse reaction of 6PGDH was 
calculated from the heavy isotope enrichment (equation 3). However the calculated 
isotope effect appears to increase by increasing the extent of the reaction (Fig. 34). 
This result is surprising, in fact the presence of an hydrogen exchange occurring 
independently from the reductive carboxylation should eventually decrease the 
measured isotope effect. Because the main change occurring during the T(V/K) 
measurements was the build up of the 6PG in the reaction mixture, we measured the 
deuterium isotope effects in the reverse reaction both in the presence and in the 
absence of 6PG. In the absence of 6PG  D(V/K) and D
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respectively. A D(V/K) lower than D(V) means that cfV is lower than cf (eq. 9 eq.7), 
and from the definition of the commitment factors (eq. 6 eq.4) it follows that 
1/k4>(1/k7+1/k9+1/k11)                                                                                     (11) 
This means that all the steps following the proton abstraction from the Ru5P are 
faster than the release of Ru5P or, in other word, that the chemical steps and the 6PG 
release are not rate limiting.   
In the presence of 40 µM 6PG D(V/K) increases and D(V) decreases (2.84 and 1.38 
respectively). The increase of D(V/K) correlates with the observed increase of T(V/K) 
when 6PG accumulates in the reaction mixture. A D(V/K) > D(V) means that the 
relation 11 is reversed, and that the presence of 6PG changes the rate limiting step of 
the reaction. 
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                    Fig. 34. Tritium isotope effect on the V/KRu5P in the reverse reaction of 6PGDH 
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Inhibition of the reductive carboxylation by 6PG 
 
6PG is known as competitive inhibitor toward Ru5P in the reverse reaction of the 
6PGDH. We have reinvestigated the inhibition by 6PG, and we observed that at low 
concentration the inhibitor slightly increases the rate of the reaction. At higher 
concentrations 6PG behaves as a conventional competitive inhibitor (Fig. 35), with a 
Ki 9.3 µM, but back extrapolation of the enzyme activity to zero 6PG give an 
enzymatic activity about five fold higher than the activity really measured.  
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     Fig. 35. Effect of 6PG on the reductive carboxylation by C. utilis 6PGDH.    
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These data suggest that 6PG has a double effect: it activates the reverse reaction, 
probably by removing a rate limiting step, and inhibits the reaction by competing 
with the Ru5P. 
The effect of 6PG on the reverse reaction of 6PGDH was totally unexpected. At 
relatively high concentrations 6PG behaves as classical competitive inhibitor. 
However at low concentrations of 6PG, when the two subunits of the dimer are 
occupied at the same time by 6PG and Ru5P, the enzymatic activity increases, 
meaning that when 6PG is bound to one subunit, the catalytic activity of the other 
subunit increases. These results can be correlated with the previously reported 
observation that 6PG increases the rate of decarboxylation of the 3-keto-2-deoxy-
6PG (3Kdo6PG), an analogue of the putative reaction intermediate 3-Keto-6PG. 
6PGDH from sheep liver does not decarboxylate the 3Kdo6PG, but 6PG is able to 
induce the decarboxylation even in the absence of coenzymes [34]. Also for 6PGDH 
from other sources, that slowly decarboxylate the 3Kdo6PG, the presence of 6PG 
increases the rate of decarboxylation by over one order of magnitude [35]. Taking 
together the old and the new evidences it appears clearly that the maximum efficiency 
in the catalytic reaction requires a 6PG bound to one subunit, while the catalysis 
occurs at the other subunit. 
 
As reported above, in the absence of 6PG the deuterium isotope effects indicate that 
k4 is the slowest step, meaning that in the forward reaction (from 6PG to Ru5P) the 
product release should be rate limiting. This result is conflicting with the previously 
reported data [74] showing that the first steps of the forward reaction, isomerisation 
of the enzyme-NADP-6PG complex, dehydrogenation and decarboxylation, are rate 
limiting. Apparently there is a violation of the principle of microscopic reversibility. 
When the isotope effects are measured in the presence of 6PG, despite the inhibition, 
the value of D(V/K) increases while the value of D(V) decreases, meaning that under 
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these conditions k4 is not rate limiting (Table 11). It should be noted that the 
measurements of the forward reaction are necessarily carried out in the presence of 
6PG,  therefore when the experiments are carried out under condition more similar to 
that used for the measurements of the forward reaction the principle of microscopic 
reversibility is satisfied. This change in the rate limiting steps is confirmed by the 
change of T(V/K), that increases as the reaction proceeds and 6PG builds up in the 
reaction mixture.  
 
 
 
 
 
 
 
Table 11.  Deuterium and tritium isotope effect on the reductive carboxylation of Ru5P by 6PGDH. 
 
This could be an effect on the chemical step itself, or on the release of the Ru5P. The 
possibility that the product release could be rate limiting has never taken into 
account, because under the usual conditions for initial rate measurements the release 
of CO2 is fast and irreversible, and Ru5P has a relatively low affinity for the enzyme.  
A more detailed analysis of the isotope effect could show whether the slow step is an 
isomerisation step, preceding the chemical steps, or also the proton abstraction and/or 
carboxylation are affected. We can take the tritium isotope effect measured at low 
substrate conversion as indicative of the T(V/K) in the absence of 6PG, and the 
isotope effect measured at high substrate conversion as indicative of the T(V/K) in the 
presence of 6PG (Table 11). Despite the uncertainty due to the experimental errors in 
the determination of the deuterium isotope effects and to the change of the tritium 
isotope effects as the reaction proceeds, for each condition, without 6PG and with 
6PG, we have three equation (D(V), D(V/K) and T(V/K) ) with four unknown (Dk5, cf, 
isotope effect parameter 
- 6PG +6PG 
D(V) 2.46 1.38 
D(V/K)Ru5P 1.68 2.84 
T(V/K)Ru5P 2.55 5.20 
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cr and cfV), and an estimate of Dk5 can be obtained by setting arbitrary values of cr in 
eq 10. 
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In the absence of 6PG, computer fitting gives a small range of cr, and when cr > 1.6, 
cfV becomes negative.  Thus from D(V/K) and T(V/K) we obtain a Dk5 ranging from 
4.90 to 4.92 (Table12).  The high values of cf (3.11-4.76) indicate that k4 is lower 
than k5.  The release of Ru5P is thought to be fast [74] so it is unlikely that k4 could 
be the Ru5P release step. To explain the low value of cf a slow step preceding the 
isotope sensitive step has been inserted in the mechanism.  This step is likely an 
isomerisation of the enzyme-substrate complex, similar to the partially limiting 
isomerisation observed in the forward reaction [74]. 
 
Dk5 cf cfV cr 
-6PG +6PG -6PG +6PG -6PG +6PG 
0 4.92 4.94 4.76 1.14 1.68 9.37 
1 4.91 4.93 3.73 0.13 0.67 8.34 
1.1 4.91 4.93 3.63 0.028 0.57 8.23 
1.6 4.90 -- 3.11 -- 0.071 -- 
 
          Table12. Calculated values of intrinsic isotope effect and commitment factors. 
 
In the presence of 6PG, the allowable values of cr are still small, and for cr > 1.1, cf 
becomes negative.  The calculated values of Dk5 are still comprised in a very small 
range, 4.93 to 4.94.  The values of cf are small (0.028-1.14) showing that either k4 
increased or k5 decreased. A decrease of k5 is unlikely, in fact we observed that 6PG 
increase the reaction rate, thus the main effect of 6PG appears to be on the 
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isomerisation step preceding the chemical steps. The allowable values of cr are very 
close both in the presence and in the absence of 6PG, suggesting that the steps 
following the proton abstraction are unaffected, or only slightly affected by the 
presence of 6PG. 
Thus Dk5 is defined in a narrow range, 4.90-4.94, and poorly affected by the presence 
of 6PG. This suggests that, despite the caveat above reported on the quality of the 
experimental data, the overall analysis of the isotope effects gives a reliable picture of 
the kinetics of the reaction. A deuterium intrinsic isotope effect of about 5 suggests 
that the transition state symmetry of the catalysed reaction is similar to that of the 
reaction in solution. 
The allowable values of cr come from several rate constants.  Nevertheless an 
approximate value for the ratios k6/k7, k8/k9, and k10/k11 can be calculated.  To do this 
we can use the values of the commitment factors determined by Cook [74,75] in the 
study by kinetic isotope effects of the oxidative decarboxylation.  It can be easily 
seen that the cf and cr in the oxidative decarboxylation are respectively the ratio 
k10/k11 and k9/k8 in the reverse reaction. 
In the study of the oxidative decarboxylation only a range of allowable values of cr 
and cf has been determined.  To choose a value, we take into account that the ratio of 
the rates of reduction and decarboxylation of 3K2do6PG [76] is about 1.5.  Thus if 
the observed rates reflect the decarboxylation (k8) and the reduction (k9), an 
appropriate value for the cr of the oxidative decarboxylation is 0.66.  Taking the 
corresponding value for cf, we can calculate the k6/k7 ratio for the reductive 
carboxylation: 
k6/k7=(cr)rev /(1+(1/cr)fw(1+(cf)fw)) 
where the subscripts rev and fw refers to the reductive carboxylation and to oxidative 
decarboxylation respectively. 
In conclusion approximate estimate of the ratios between the rate constants can be 
calculated over the whole reaction pathway, with the exception of the on/off rates of 
reactants and products. This allows to draw the upper part of the energy profile of the 
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reaction (Fig. 36), while the lower part requires the knowledge of the steady-state 
concentrations of the intermediates. It can be seen that in the absence of 6PG the rate 
limiting step is the isomerisation of the enzyme-Ru5P complex, while in the presence 
of 6PG the rate limiting step is the isomerisation of the enzyme-6PG complex. 
 
 
 
                             Fig. 36. Energy profile in function of reaction ordinate. 
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CONCLUSIONS 
 
A common feature of all the experiments here reported is the key role of the 
conformational changes in the catalytic mechanism of 6PGDH. At least two different 
conformational changes occur during the catalysis: a first one when the 6PG, or a 
6PG analogue, binds to the enzyme. This conformational change requires a large 
enthalpy increase and involves not only the residues of the active site, but also H188 
and C372. A second conformational change occurs during the catalysis, as suggested 
by the large change of the Kd of 4PE in the presence of the coenzymes. It should be 
noted that the high inhibition constant of 4PE cannot be observed in the binary 
complex, meaning that the development of new inhibitors cannot be based only on 
binding experiments. 
The conformational changes are also important in the enzyme kinetics, in fact they 
are the rate limiting steps of the reaction, both in the forward and in the reverse 
directions. 
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